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ABSTRACT
SELECTIVE INHIBITION AND MECHANISTIC STUDIES OF THE HUMAN O 2
SENSOR, PROLYL HYDROXYLASE DOMAIN 2 (PHD2)
SEPTEMBER 2011
SHANNON COATES FLAGG, B.S., UNIVERSITY OF NEVADA, LAS VEGAS
Ph.D., UNIVERSITY OF MASSACHUSETTS - AMHERST
Directed by: Professor Michael J. Knapp

Prolyl Hydroxylase Domain 2 (PHD2) has been identified as a key oxygen sensor in
humans along with Factor Inhibiting Hypoxia Inducible Factor (FIH). As such PHD2
and FIH play critical roles in myriad pathways of medical relevance by hydroxylation of
their target substrate hypoxia inducible factor (HIF), a transcription factor responsible for
the regulation of over 100+ genes. With such critical roles in human physiology the
ability to selectively regulate these two enzymes could potentially lead the way for novel
therapeutic treatments of a vast array of disease states from cancer to myocardial
infarction.
We report on three classes of iron chelators which show promise for independent
regulation of the HIF hydroxylases. Compounds representing the pyrones/pyridinones,
pyridines and catechols were tested and found to have differential impacts on PHD2 and
FIH under the same experimental conditions. The mode of inhibition is the result of
binding to the active site iron and is supported by UV-visible and electroparamagnetic
resonance spectroscopy.
PHD2 at the current time does not have a well resolved mechanistic understanding
regarding its catalytic cycle and subsequent rate determining steps. I have employed pH,
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solvent isotope, and X-ray absorption studies in an effort to gain further understanding
regarding PHD2’s overall mechanism. Our data support that dissociation of an iron(II)OH2 bond centered about the active site contributes to a portion of the overall rate
determining steps in the catalytic reaction of PHD2 that activates oxygen and ends with
the production of hydroxylated substrate.
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CHAPTER 1

OXYGEN SENSING

Introduction
Our atmosphere is 21% oxygen and by mass oxygen is the second most abundant
element of earth at 30% second only to iron at 35%. Iron and oxygen have been
incorporated into the most fundamental workings of life throughout the evolution of the
planet including the enzymes covered by this research. While oxygen is essential for
aerobic life it can also damage it through oxidation and therefore it would seem plausible
that there exist a process which regulates O2 homeostasis. Globally the need for oxygen
to sustain the majority of life on earth should be self evident. Yet beyond inhalation of
oxygen into the lungs lies a complex pathway of oxygen regulation and distribution that
is still under discovery. The lack of sustained oxygen regulation within any physiological
system can lead to disastrous effects from cellular oxidative damage due to hyperoxia or
elevated O2 levels to cellular and tissue death from hypoxia, defined as a critically low O 2
concentration. Our energy needs are regulated via oxygen as it is the final electron
acceptor in aerobic respiration leading to the production of ATP (adenosine-5’triphospate), deemed the energy currency of the body. Aerobic respiration generates 2930 ATP, whereas anaerobic respiration or glycolysis only generates a net of 2ATP’s,
making aerobic respiration 19 times more efficient 1. Normally throughout human
physiology oxygen concentrations vary widely from ~21% in the lungs to as low as ~1%
at the corticomedullary junction of the kidneys. Despite this wide range in which oxygen
must be regulated within any given location of the body, there exists a tightly controlled
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regulatory system to keep this vital element in check. Leading the regulation of this
pathway is the transcriptional regulator Hypoxia Inducible Factor (HIF) discovered in
1992 as being required for the transcription of erythropoietin (EPO) in humans, which
leads to red blood cell production and subsequently oxygen delivery2. To stress the
significance of this pathway, consider a tumor which by its very nature is hypoxic and
requires O2 via the vascular system to sustain its growth and existence; regulate the
system and just possibly, regulate the tumor. There are many other instances in which
hypoxia is a major contributing factor to the pathophysiology of the underlying problem
aside from cancer like stroke and myocardial infarction3.

While HIF is the main

transcription factor regulating genes involved in oxygen homeostasis it has its own set of
master controllers which are iron(II), α-ketoglutarate dependent hydroxylases, Prolyl
Hydroxylase 2 (PHD2) and Factoring Inhibiting Hypoxia Inducible Factor (FIH). These
two enzymes ultimately determine whether or not HIF is able to transcribe genes in
response to O2 changes in localized environments. Acquiring knowledge of the oxygen
delivery pathway and its regulators may possibly lead to extensive new ways in which to
combat some of the most prevalent health disorders that plague our existence.

Hypoxia Inducible Factor (HIF)
Variation in oxygen availability requires an adaptive response to cope with these
changes. The variation in oxygen availability may be due to something as simple as a
change in altitude to a disease state within the body. Whatever the underlying cause, HIF
is the key to balancing the system. HIF is comprised of two subunits, the α and the β.
HIF-1β is constitutively expressed while the HIF-1α subunit is tightly regulated through
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prevalent oxygen concentration4, 5. It is important to note that there are three isoforms of
HIF, HIF-1, HIF-2 and HIF-3 and it has been determined that the primary oxygen
regulator of the isoforms is HIF-1 and therefore focused upon in this research6-8. The
individual domains of the α and β subunits contain a basic-Helix-Loop-Helix and PerARNT-Sim (bHLH-PAS) regions necessary for heterodimerizaiton and DNA binding,
and are located at the amino terminal half of the construct.

HIF-1β initially was

identified as the Aryl Hydrocarbon Receptor Nuclear Translocator protein (ARNT), as it
was found to dimerize with the aryl hydrocarbon receptor upon binding of aryl
hydrocarbons as is the case with dioxin9. ARNT domains are typical amongst a vast
family of bHLH-PAS heterodimeric transcription factors. At the carboxy terminus of
HIF-1α lies the C-Terminal Transactivation domain (CTAD) as well as the Oxygen
Dependent Degradation Domain (ODDD)10, 11. It is through the CTAD and the ODDD
domains that transcription leading to over hundred plus genes are regulated via available
oxygen concentrations (Figure 1.1). Some of the key genes regulated via HIF-1 are
responsible for angiogenesis, erythropoiesis, iron regulation, anemia, and energy
metabolism to mention a few.

Figure 1.1 The domains of HIF1-α/β showing the sites of proline and asparagine
hydroxylation that regulate HIF.
During conditions of normoxia or the state in which a particular tissue, organ, or cell has
adequate O2 available as deemed normal for the local environment, HIF-1α is rapidly
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degraded with a half-life of less than five minutes4. If the oxygen requirements of the
local environment are not satisfied, hypoxia ensues and HIF-1α is stabilized. As the
oxygen concentration drops a direct relationship with increased HIF-1α levels is
witnessed12,

13

. In the presence of adequate oxygen two enzymes, prolyl-hydroxylase

domain 2 (PHD2) and factor inhibiting hypoxia inducible factor (FIH) hydroxylate HIF1α at specific residues, Pro402, Pro564 or Asn803 respectively. The α-subunit is then either
rapidly degraded through a ubiquitin-proteasome pathway in the case of PHD2 or is
blocked from interaction with specific transcription factors necessary for gene expression
in the case of FIH12-19.

HIF Hydroxylases
The HIF hydroxylases are the major regulators of the hypoxic response in humans by
acting upon HIF-1α ultimately determining its ability to regulate genes crucial in the
hypoxia pathway. There are three isoforms of PHD found in humans, (PHD 1,2,3) and a
asparaginyl hydroxylase, FIH. PHD2 and FIH are Fe(II) αKG dependent dioxygenases
that utilize O2, and couple the hydroxylation of the substrate to the oxidative
decarboxylation of αKG to succinate and CO2 (Figure 1.2)20, 21.

Figure 1.2 The consensus mechanism for the HIF hydroxylases
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The overall reaction for the HIF hydroxylases involves a shift from a six coordinate
resting enzyme to a five coordinate state that is primed for reaction with oxygen. Once
αKG binds, two water molecules are displaced and as substrate docks it is thought that
this triggers release of the last water molecule opening a coordination site available for
oxygen chemistry to occur.

Once active the enzyme couples the hydroxylation of

substrate where one of the oxygen atoms is inserted into succinate, resulting from
oxidative decarboxylation of αKG, and the second oxygen atom is incorporated into the
product, i.e. substrate. Some studies report a lower KM for O2 with respect to PHD2 than
for FIH, but in general the KM for O2 for both enzymes is higher than ambient oxygen
concentrations. This high level of KM indicates that relatively small changes in O2
concentrations can have a significant impact on PHD2 and FIH activity22,

23

.

This

difference in KM for the HIF hydroxylases also suggests that once PHD2 has been
suppressed by insufficient O2 HIF-1α is able to escape degradation, however FIH still
remains active altering its transcriptional activity24, 25. For example, in 1% O2 FIH is still
active while PHD is fully suppressed, this seemingly supports that FIH is the primary O2
sensor under hypoxic conditions26. Another factor regarding the true KM of oxygen for
these enzymes is that it ranges with varied substrate length and at the current time success
has not been achieved in expressing full length HIF-1α and so synthetic peptides are
employed for substrate-enzyme interaction and kinetic studies23.

Prolyl Hydroxylase Domain 2 (PHD2)
Initially discovered in C. elegans the prolyl hydroxylases (PHD1, PHD2, PHD3) have
been determined to be the key oxygen regulatory enzymes along with an asparaginyl
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hydroxylase, factor-inhibiting HIF (FIH) in humans. Each of the PHD’s differs in the
amount of their mRNA but all have a ubiquitous mode of expression27. Despite there
being three isoforms each of which must have specific roles it was determined by siRNA
research that the silencing of PHD2 was enough to fully stabilize HIF1α and thereby was
deemed the primary O2 sensor of the PHD’s28. PHD2 is an iron(II), α-ketoglutarate
dependent enzyme belonging to the dioxygenase family which utilize molecular oxygen
in the oxidative decarboxylation of α-ketoglutarate to succinate and CO2 release coupled
to hydroxylation of their target substrate. PHD2 targets two proline residues within the
HIF-1α domain, Pro402 in the NODD (N-terminal Oxygen-Dependent Degradation
Domain) and Pro564 in the ODDD (Oxygen Dependent Degradation Domain).

The

hydroxylation of either or both triggers the degradation of HIF-1α via a ubiquitin ligase
pathway. It should also be noted that prolyl hydroxylation is substantially more sensitive
than asparaginyl hydroxylation to inhibition by iron chelators and transition metal ions
and that the order of suppression of hydroxylation follows as Pro 402>Pro564>Asn803(29).
When PHD2 hydroxylates HIF-1α the end result is proteosomal degradation, which is
vastly different than the result of asparaginyl hydroxylation which alters transcriptional
activity.

PHD2 is commonly located in the cytoplasm and is suggested to be the

dominant isoform of the three under normoxic conditions with the highest level of
expression occurring across a range of cell types30-32.

Factor Inhibiting Hypoxia Inducible Factor (FIH)
HIF-1α’s second major regulator is FIH. FIH hydroxylates Asn803 of the CTAD domain
on the β-carbon which is independent of the prolyl hydroxylase modifications in the
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ODDD33-36. This event prevents the interaction of HIF-1α with the transcriptional coactivator p300 also known as CREB-binding protein.

The end result of this

hydroxylation is the halting of all p300 dependent transcription, but not the degradation
of HIF-1α as is the case with prolyl hydroxylation. FIH like PHD2 is also commonly
found in the cytoplasm. It should be noted that the distribution of PHD2 and FIH does
differ depending on the mitigating circumstances of the local biology. For example, it
has been demonstrated that the PHD’s are strongly expressed in the cytoplasm of normal
bronchial epithelium and weakly in fetal lung bronchial epithelium, while expression is
nuclear in the chondrocytes37. FIH expression is strongly expressed in the cytoplasm of
normal bronchial epithelium and nuclear expression exists in the bronchial cartilage. FIH
in sharp contrast to PHD displays a strong expression in the fetal bronchial epithelium
highlighting the differential regulation upon the same substrate between the two
enzymes37. The contrasting outcomes on HIF-1α regulation by the HIF hydroxylases is
demonstrated in Figure 1.3.
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Figure 1.3 The pathway of HIF-1α as directed by the HIF hydroxylases PHD2 and FIH.
In the presence of O2 FIH hydroxylates HIF-1α on Asn803 blocking interaction with the
transcription factor P300, halting all P300 dependent transcription. PHD2 hydroxylates
either Pro402 or Pro 564, or both leading to proteosomal degradation by signaling the
binding of the von Hippal Lindau protein (pVHL) part of ubiquitin ligase complex. In
the absence of O2 HIF-1α is able to dimerize with the β-subunit triggering transcriptional
activity. Figure courtesy of Saban, E38.
The Oxygenase Family of Enzymes
Members of the oxygenase super-family of enzymes are found throughout prokaryotes
and eukaryotes and execute a variety of chemistry. The reactions catalyzed in this family
include ring opening/closing, desaturations, eliminations, halogenations, epoxidations
and focal to this research, hydroxylation reactions39-42. These reactions have significant
roles in the biosynthesis of collagen, antibiotics, alkylated DNA repair, secondary
metabolites generated from plants and microbial sources, and key to this work, cellular
oxygen sensing40, 42-45. By studying related enzymes in this family it may be possible to
gain further insight and knowledge about the less well understood mechanisms of other
oxygenase enzymes like PHD2 and FIH. A simplified version of the hydroxylation
reaction executed by members of this family including FIH and PHD2 is depicted below
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in which αKG and O2 are utilized in conjunction with substrate generating succinate, CO 2
and product.

The αKG dependent enzymes inclusive of PHD2 and FIH are part of a subfamily of the
non-heme iron(II) containing superfamily of enzymes.

These enzymes possess a

His2 Asp/Glu facial triad about their iron core and catalyze a vast array of reactions.
Heme containing enzymes possess four coordination sites occupied by the porphyrin of
heme and a fifth coordination site occupied by one proximal residue thereby leaving only
one available site for the binding of O2. In contrast, the non-heme class involves an iron
coordination environment formed from three endogenous protein ligands leaving three
coordination sites available for cofactors and substrates. This non-heme superfamily can
be subdivided into multiple classes which include the extradiol cleaving catechols
dioxygenaes, α-ketoglutarate dependent dioxygenases, tetrahydropterin dependent
hydroxylases,

bacterial prolyl

hydroxylases

and

biosynthetic oxidases39,

46-49

.

Examination of these enzymes may provide insightful information regarding the HIF
hydroxylases as key intermediates for FIH and PHD2 have yet to be isolated.

Related Oxygenase Enzymes of Interest

Extradiol Cleaving Catechol Dioxygenaese
The extradiol cleaving catechol dioxygenases perform ring cleavage reactions of aromatic
compounds50-52. The best understood of these enzymes is homoprotocatechuate 2,3dioxygenase (HPCD). In an effort to gain mechanistic insights to this class of enzymes
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an alternative and slow reacting substrate was employed for HPCD, 4-nitrocatechol, a
compound also employed for purposes of the body of work contained within this thesis.
The knowledge gained from this work was the revealing of three distinct intermediates
generated during the catalytic cycle (Figure 1.4).

Figure 1.4 Catalytic mechanism of extradiol catechols dioxygenase
Intermediate one is a Fe(II)-O2 complex that determined the Fe-O bond length to be 2.4 Å
and that the 4-nitrocatechol ring is not planar, suggesting that iron is maintained in the
Fe(II) state and that substrate gives one electron to activate oxygen. Intermediate two is a
Fe(II)-peroxo-substrate complex whereby oxygen attacks the C2 of 4-nitrocatechol
generating a peroxo bridge. The third intermediate found is the Fe(II)-product complex.
The resulting data from these crystallized intermediates provides evidence regarding key
residues with the active site which form hydrogen bonds that aid in the stabilization of
the deprotonated substrate and in promoting heterolytic dioxygen bond cleavage46, 53-58.
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Tetrahydropterin Dependent Hydroxylases
The tetrahydropterin dependent hydroxylases generate hydroxylated aromatic amino acid
residues through the donation of two-electrons from tetrahydropterin. In this example
which is believed to be similar to the HIF hydroxylases, the binding of substrate and
cofactor at iron generates an open coordination site for the binding and subsequent
reaction of oxygen. Once bound, oxygen forms a peroxo-bridge from the Fe(II) to the
cofactor. Heterolytic O2 bond cleavage generates a 4a-hydroxypterin and a Fe(IV)=O
intermediate species59, 60. Upon the formation of the highly reactive Fe(IV)=O species it
is then able to abstract a hydrogen from the nearby substrate, as is believed to be the case
with the HIF hydroxylases. This hydroxyl group proceeds through a rebound mechanism
to a radical substrate and the completion of the cycle ending in the hydroxylated product
(Figure 1.5)61.

Figure 1.5 Aromatic amino acid hydroxylase mechanism
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α-Ketoglutarate, Iron (II) Dependent Oxygenases

Taurine:αKG dioxygenase (TauD)
TauD is a taurine (2-Aminoethanesulfonic acid), αKG dependent dioxygenase from E.
coli that catalyzes the oxygenolytic release of sulfite from taurine utilizing αKG,
molecular oxygen and Fe(II), producing succinate, CO2 and sulfite as by-products of the
reaction62. In a reaction quite similar to that of PHD2, studies of TauD have provided
great insight into the potential workings of the HIF hydroxylases as they are in the same
sub-family of enzymes.

In particular, TauD revealed a highly reactive Fe(IV)=O

intermediate and provided evidence for the hydrogen abstraction by a non-heme ferryl
complex63, 64. TauD also revealed a secondary oxygen activation mechanism. In the
absence of prime substrate TauD performs a self-hydroxylation reaction which renders
the enzyme dead65. This auto-hydroxylation reaction has also been witnessed in FIH and
questions whether or not this is a safety-net mechanism guarding from oxidative damage
by the oxygen sensing HIF hydroxylases38. This mechanism has not been supported in
PHD2 but it is suspected.
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Figure 1.6 The hydroxylation reaction of TauD65
Collagen Prolyl-4-Hydroxylase (P4H)
Collagen Prolyl-4-hydroxylase is also a αKG, iron(II)-dependent dioxygenase that crosslinks human collagen helices in the connective tissues by hydroxylating proline
generating the formation of 4-hydroxyproline residues.

Without this vital enzyme

collagen is unable to fold into its natural triple helical molecules. A direct result from
lack of P4H activity is the development of scurvy, a disease associated with lack of
vitamin C (ascorbate) that cumulates in weak connective tissues leading to open lesions.
Interestingly enough, ascorbate is believed to help maintain the Fe(II) state in these
enzymes as oxidation to Fe(III) renders the enzyme inactive. PHD2 like P4H also
requires ascorbic acid for repetitive turnover. The reaction catalyzed by P4H is depicted
in Figure 1.7.
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Figure 1.7 Reaction catalyzed by P4H
The prolyl hydroxylase enzymes catalyze the most prevalent posttranslational
modifications in humans by the formation of 4-hydroxyproline, this is in no small part
because collagen is the most abundant protein found in the body66.

The Bacterial Proline/Prolyl 4-Hydroxylases (P4H)
A key difference in the bacterial prolyl 4-hydroxylases is that hydroxy-proline is
generated from a free proline versus a peptidyl proline67. As these enzymes catalyze the
hydroxylation of free proline they are deemed proline hydroxylases instead of prolyl.
There are prolyl hydroxylases found in bacteria like anthrax-P4H that binds to a (GPP)10
collagen-like peptide. These enzymes lend themselves as informative to the overall
mechanism underlying their close relatives, the prolyl hydroxylases. They are members
of the non-heme iron(II), αKG, dioxygenase family that require molecular oxygen but
have less stringent requirements for substrate than the prolyl version68. The structural
analysis of the bacterial P4H’s have yielded information about charged residues that play
integral roles in the binding of substrate, providing a framework for similar studies on
PHD2 and FIH.
All the prolyl and proline hydroxylases utilize O2, αKG and iron(II). The activity of
these enzymes is known to increase in magnitude with the addition of ascorbate,
presumably acting as a reducing agent maintaining iron in the 2+ state. They all contain a
14

highly conserved iron binding motif with rare exceptions. Sequence homology amongst
these enzymes is almost nonexistent and yet they share a similar three-dimensional
structure classified as the β-barrel jelly roll fold (Figure 1.8 ).

Figure 1.8 Example of the β-barrel jelly roll fold for the prolyl hydroxylases FIH and
PHD2 and including a zoomed view of their iron(II) facial triad (PDB 1H2M, 2G19).
Figure created with PyMol.

Based upon knowledge gained from the aforementioned enzymes and their isolated
intermediates a mechanism for the HIF hydroxylases is proposed in Figure 1.9. In PHD2
only the accumulation of an Fe(II) species has been witnessed and precisely which Fe(II)
form that is has not been resolved69.
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Proposed Mechanism for the HIF Hydroxylases

Figure 1.9 Proposed mechanism of the HIF hydroxylases PHD2 and FIH. Mechanism
begins with 6 coordinate iron, αKG displaces two H20 molecules, substrate binding
triggers last H2O molecule to exit opening a site for O2 activation. The subsequent steps
are proposed and have yet to be supported until the release of hydroxylated substrate and
a regeneration of the resting state enzyme.
Of interest in this mechanism are the steps that involve αKG binding and the docking of
substrate. When substrate docks it is proposed to release the last H2O molecule opening a
site for oxygen activation. At this point in the reaction there exists an opportunity to halt
activity by the introduction of inhibitors which could bind similarly to αKG. Excluding
the ability of αKG from binding by mimicking it in the form of an inhibitor may lead to
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novel therapeutic treatments in the future. This possibility is currently under exploration
and had yielded informative information regarding the potential to selectively inhibit
PHD2 and/or FIH which will be a topic of discussion within this thesis. A secondary
topic up for discussion regarding the mechanism of PHD2 is to gain a more robust picture
of the individual steps involved in the mechanism, specifically rate-limiting steps that are
essential to catalytic turnover. Exploration of this latter topic can in turn be used to
further the first aim of selective inhibition of the HIF hydroxylases.
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CHAPTER 2

SELECTIVE INHIBITION OF THE HIF HYDROXYLASES PHD2 AND FIH

Introduction

The potential for treatment of various disease states via the inhibition of the HIF
hydroxylases is a current goal amongst researchers. The ability to reduce sensitivity to
hypoxia through possible preconditioning towards hypoxia may provide novel therapies
for the treatment of ischemic disorders such as stroke and heart attacks. These enzymes
play pivotal roles in the inflammatory response, anemia, metabolism, red blood cell
production and vascularization to mention a few and are prime for therapeutic targeting
in which myriad diseases could be ameliorated. PHD2 and FIH share a similar structure
and utilize the same cofactors, even acting upon the same substrate. They do however
have their differences with respect to the docking of co-factors and the coordination
environment surrounding the active sites of each that should allow for selective
inhibition.
Comparisons of PHD2 and FIH Active Sites
The target for selective inhibition of these enzymes is their iron-centered active site
which does pose some challenges as these sites are highly conserved in PHD2 and FIH 21,
70-72

. Both active sites possess a 2-His/1-Asp facial triad about the iron center and both

enzymes are dependent on the same cofactors for activity and target the same substrate,
HIF1-α, albeit at different locations. Key differences between PHD2 and FIH are with
respect to their Fe(II) and αKG binding sites. While both possess the HXD/E..H facial
triad the binding in PHD2 is tighter, with affinities for the binding of iron, (~0.01-0.03
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µM) for PHD2 and (~0.5 µM) for FIH73. This fact may partially be explained by the
smaller active site of PHD2. The orientation of the aspartate ligand in FIH is different
than PHD2, it coordinates to the iron and to the backbone of the substrate while in PHD2
the aspartate ligand coordinates to the iron and a well resolved water molecule in the
crystal structure.

Measurement of the active site pockets reveals that for the non-

substrate bound form of PHD2 the pocket size ranges between 319-355Å3 (PDB’s 2G1M,
2G19, 3OUJ, 2HBT, 2HBU) and that of FIH 1005-1222 Å3 (PDB’s 1H2N, 1MZE,
1MZF, 2CGN).

In the presence of substrate the active site pocket shrinks in both

enzymes but far more drastically in FIH, 242-497 Å3 (PDB’s 1H2M, 1H2L, 1H2K)
versus PHD2 167-344 Å3 (PDB’s 3HQR, 3HQU). Thus each enzyme in theory should
produce a differential response to an identical inhibitor. This difference coupled with the
fact that and they share virtually no sequence homology despite sharing similar structures
lends itself to the possibility of selective inhibition. Another key difference is that FIH
requires a dimeric state for catalysis while PHD2 functions in a monomeric state. FIH
can also be catalytically active with only the two histidines bound to the iron74. The
PHD2 pocket is actually deeper than that of FIH and predominantly hydrophobic in
nature consisting of residues Ile256, Met299, Ala301, Tyr303, Tyr

310

, Thr325, Ile327, Tyr329,

Leu343, Phe366, Val376, Ala385, Thr387, and Trp389. This hydrophobicity may function to
help guard PHD2 from possible oxidative damage that could arise from Fenton chemistry
about the iron center70. FIH also exhibits a similar hydrophobicity in its shallower active
site pocket, the contributing residues are from, Ile256,Met299, Ala301, Tyr303,Tyr 310, Thr325,
Ile327, Tyr329, Leu343, Phe366, Val376, Ala385, Thr387, and Trp389. PHD2 appears to involve
an induced fit mechanism that results in almost completely blocking the active site as a
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loop closes over the entrance upon substrate binding75, 76. Other key differences in the
enzymes have to do with specific residues that make up the second coordination sphere
about the iron core and contribute to hydrogen bonding networks about the iron and αKG
binding sites. Of particular interest is Gln147 in FIH which has its mirror in PHD2’s
Ala301.

The longer side chain in FIH is in position to clash with certain aromatic

inhibitors like {[(4-hydroxy-8-iodoisoquinolin-3-yl) carbonyl] amino} acetic acid which
was employed for the crystallization of PHD270.

This compound has proven a viable

inhibitor of PHD2 while not impacting the activity of FIH, presumably due to an inability
to gain access to the iron due to steric clash. A residue of interest in PHD2 is Val376
which forms a steric clash with the D-enantiomer of N-oxylylglycine (NOG). PHD2 and
FIH are also members of separate subfamilies of the α-KG oxygenases dictated by the
location and function of their C-terminal helices relative to their active sites. In FIH
these helices are required for dimerization, while PHD2 does not dimerize for catalytic
activity35. This coupled with the abovementioned differences between these enzymes
lays the framework for ferreting out selective inhibitors of each.

Known Inhibitors
It has been found that N-oxylylglycine (NOG) and dimethyl N-oxalylglycine (DMOG)
have the capability to inhibit both enzymes77.

This inhibition is achieved through

bidentate binding to the iron, as both of these compounds are structurally similar to αketoglutarate. While these inhibitors halt activity in other oxygenases and are therefore
not selective, derivatization which resulted in N-oxalyl amino acid inhibitors did support
that as the side chain increased the level of inhibition decreased for PHD2 and a
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preference for the L-N-oxalyl derivatives over the D-N-oxalyl forms was noted78. The
effects on FIH supported a preference for the

D-enantiomer

forms with the N-

oxalylphenylalanine derivative showing selective inhibition for FIH over PHD2,
suggesting that bulk and hydrophobicity could serve to distinguish between the
enzymes78. Selective inhibition has also been explored with elaborated isoquinolines79, 80
and imidazo[1,2-a]pyridines81 which have been reported as potent inhibitors of PHD2
(IC50~1 uM) . 4-Oxo-1,4-dihydro-1,10-phenanthroline-3-carboxylic acid was found to
inhibit FIH and PHD, with an IC50 of 60 M for FIH and a Ki of 10 M for PHD2. Even
among non-specific iron chelators research supports that N-oxalyl-D-phenylalanine
(NOG) and desferrioxamine (DFO) both of which are strong chelators display differential
inhibition between FIH and PHD222, 70, 78. Another comparison involving DFO and DIP
(dipyridyl), another strong metal chelator, noted that DIP halted FIH associated
hydroxylation at high doses while DFO did not. This is indicative that more interactions
are at play than just simple chelation26.

Inhibitor Classes Tested for Selective Inhibition
Selection of inhibitors was based upon the structural ability to chelate iron in a bidentate
manner like α-ketoglutarate.

The compounds tested come from the pyridine,

pyrone/pyranone and catechol chemical classes (Figure 2.1). The goal is to start with
basic chelating groups to exploit differences between the HIF hydroxylases and
selectively inhibit each, with the future goal of designing more selective inhibitors based
on the results of this work. Within each class of compounds are variations that introduce
different substituents on the base compound that may potentially enhance or disrupt
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hydrogen bonding networks within the αKG binding pocket, and that explore the volume
difference of the active sites by the introduction of bulky side groups.

Figure 2.1 Inhibitors tested. (1)CNP, 3-cyano-6-methyl-2(H) pyridinone(2)NOP,
hydroxypyridine 1-oxide , (3) DHP, 2,3-dihydroxypyridine, (4) Hop-OH, 5-hydroxy-2hydroxymethyl-4-pyrone, (5) Hop-COOH, 5-hydroxy-4-oxo-4H-pyran-2-carboxylic acid,
(6) Hop-Me, 3-hydroxy-2-methyl-4-pyrone, (7) HOPO, 3-hydroxy-1,2-dimethyl-4(1H)pyridinone, (8) 4NCat, 4-nitrocatechol, (9) MeCat, 4-methylcatechol, (10) BuCat, 4-tertbutylcatechol.
Pyrones/Pyridinones
Pyrones are a class of compounds containing an unsaturated six-membered ring inclusive
of one oxygen atom and a ketone functional group. The compounds selected for this
body of work are (4) Hop-OH, 5-hydroxy-2-hydroxymethyl-4-pyrone, (5) Hop-COOH,
5-hydroxy-4-oxo-4H-pyran-2-carboxylic acid, (6) Hop-Me, 3-hydroxy-2-methyl-4-
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pyrone, (7) HOPO, 3-hydroxy-1,2-dimethyl-4(1H)-pyridinone. Coordination to the iron
is likely to occur via the hydroxyl and keto functional groups as is seen with other
metalloproteins82. These compounds are viable building blocks for selective inhibition as
they are known to be safe for human consumption and they chelate metals. For instance,
(4) Hop-OH,5-hydroxy-2-hydroxymethyl-4-pyrone, aka kojic acid is commonly found
throughout the food and cosmetic industries, (5) Hop-COOH, 5-hydroxy-4-oxo-4Hpyran-2-carboxylic acid, aka comenic acid is deemed safe and is under study for a
potential anti-inflammatory and neuroprotection use83.

(6) Hop-Me, 3-hydroxy-2-

methyl-4-pyrone, aka maltol, is a naturally occurring compound found in the food chain
and is prominently used as a flavor enhancer, like kojic acid it can chelate metals. (7)
HOPO,

3-hydroxy-1,2-dimethyl-4(1H)-pyridinone,

aka deferiprone,

is currently

employed as an oral drug that chelates iron84.
Pyridines
The pyridines are heterocyclic organic compounds containing a saturated six-membered
ring with nitrogen. The compounds selected for testing include, (1) CNP, 3-cyano-6methyl-2(H)-pyridinone, (2) NOP, hydroxypyridine-1-oxide and, (3) DHP, 2,3dihydroxypyridine. Pyridine derivates are known to chelate metal and the cyano group of
3-cyano-6-methyl-2(H) pyridinone is a known inhibitor of cytochrome C oxidase85.
Hydroxypyridine 1-oxide is not a naturally compound but is rapidly degraded with a halflife of less than a week in soil microorganisms86. Also making these compounds of
interest is that pyridines and dihydroxypyridines can proceed through a degradation
pathway that is mediated by oxygenases87.
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Catechols
Catechols and their derivatives are known to chelate metals very tightly. They are used in
a variety of flavors and fragrances and also as precursors to pesticides with small
amounts occurring naturally in fruits and vegetables. The catechols under investigation
for this study are, (8) 4NCat, 4-nitrocatechol, (9) MeCat, 4-methylcatechol, and (10)
BuCat, 4-tert-butylcatechol. Each compound provides a basis for exploiting the volume
of the active site by varying the side group. Also, as the side group varies so does the
hydrogen bonding network within the αKG binding site. 4-nitrocatechol has been found
to function as a secondary substrate for a Mn(II)-dependent extradiol-cleaving
dioxygenase via bidendate binding at the iron active site, making this compound
particularly interesting88.
Materials and Methods
Protein Expression and Purification
Full length PHD2 has proven troublesome to express and purify in its full length form.
Hence, using the catalytic domain of this protein which includes residues 177-426 lessens
the challenge of expression and purification while still supporting an active enzyme. To
aid in successful purification constructing the gene within a plasmid that contains a tag is
desirable. The Stratagene pGEX-4T-1 plasmid provides the necessary solution (Figure
2.2). The vector map shows the insertion region for the chosen gene lies between a
glutathione S-transferase tag and an ampicillin resistance gene. The initial region of the
insertion area contains a thrombin cleavage site for removal of the GST tag from the
recombinant protein when required. The insertion region contains six restriction enzyme
sites where the target gene may be inserted. Starting with full length human PHD2
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contained within pcDNA3.1 plasmid for eukaryotic protein expression primers are
designed to clone out the region of interest. Cloning out the gene of interest allows for
insertion

into

a

bacterial

vector

expression

system.

The

5’

primer

(CGGATCCCGGCCCAACGGGCAGAC) anneals on the gene at residue 177 and
contains a BamHI restriction enzyme site within the primer to allow insertion into the
pGEX-4T-1

vector.

The

3’

primer

is

designed

in

the

same

fashion

(CATTTCTGCAGAAGATCCTTAAGG) and contains an EcoRI restriction enzyme site.
The restriction enzymes sites within the primers initially produce flaps on either end of
the target which after several rounds of PCR will become

Figure 2.2 Stratagene pGEX-4T-1 Vector used for expression and purification of PHD2
catalytic domain consisting of residues 177-426. Figure from Stratagene protocol.
part of the target gene sequence with two restriction enzyme cut sites allowing the gene
to be inserted into the pGEX vector between the BamHI and EcorRI sites. The PCR
program cycle for this protocol which promotes the annealing of the PHD2 gene into the
pGEX vector is as follows, 90 °C for 30 seconds, 50°C for 30 seconds, 72 °C for 1
minute, this cycle is repeated for 30 times followed by a 5 minute cycle of 72°C . To
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prepare both the pGEX vector and the newly amplified gene for fusion both require
treatment with the BamHI and EcoRI restriction enzymes which target the sequences
G/GATCC and G/AATTC respectively. Both of these restriction enzymes produce
‘sticky ends’ producing the cuts for the insertion of PHD2 into the vector.

After

individual digestion of both the vector and the PHD2 gene the final products will be
linear DNA molecules. It is then necessary to treat each product with a PCR purification
kit (QIAquick PCR Purification Kit by Qiagen) to remove all restriction enzymes and
buffer components of the reaction except for the dsDNA. At this point there are still two
individual products, linear pGEX and linear PHD2 gene. The two products are mixed in
a PCR reaction tube at a ratio of one vector to three gene products as this is considered
the industry standard based on published protocols. To achieve the proper ratio it is
necessary to obtain the concentrations of each product by measuring the absorbance at
260nm. Although it is possible to roughly determine concentrations by running a DNA
agarose gel using a known amount of an appropriate marker the more accurate result will
be achieved from absorbance data.

Once mixed the sticky ends produced by the

restriction enzymes will anneal and ligase is added to the mixture to seal the gaps. This is
achieved by mixing the vector and inserting in a 1:3 ratio respectively, adding ligase and
allowing to sit at room temperature for about five minutes. The ligation product is now
ready for transformation into a competent cell line. The competent cell line used is
Stratagene XL1-blue as this particular line of cells is designed for the uptake and copying
of DNA versus a cell line that is designed for protein expression. Competent cells can be
purchased or prepared based upon several published protocols. Competent cells must be
stored at the bottom or a -80°C freezer as they are extremely sensitive to temperature
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fluctuations and may lose their ability to take up plasmids if the temperatures are varied
too much or too often.

Aliquots of 100µL should be removed from -80°C and

immediately placed on ice to thaw. This process takes roughly five to eight minutes at
which point the cells are ready for use. Using the Stratagene protocol for the cell line,
dsDNA amounts of 0.1-50ng can be used per aliquot of cells. This number must be
experimentally determined for each plasmid and several different amounts should be
tested to ascertain the optimal amount. Approximately 30-40ng of dsDNA pGEX-4T-1PHD2 is mixed with the XL1-Blue cells and Strategene’s transformation protocol for this
cell line is then followed. In brief, mix dsDNA with cells, incubate on ice for 30 minutes,
heat shock for 45 seconds, allow recovery on ice for 10 minutes, add LB growth media
and incubate with vigorous shaking for one hour. Fresh LB agar plates containing
0.1mg/ml of ampicillin should already be prepared and pre-warmed at 37°C prior to use.
After the one hour of incubation, plate the transformed cells on the agar plates and
incubate overnight at 37°C or at least 16 hours. If transformation is successful colonies
should be visible on the plate, if not then troubleshooting of the transformation process
will be required.

Selection of multiple colonies are extracted from the plates and

prepared 5mL mini cultures containing 0.1 mg/ml of ampicillin are inoculated for the
cultures to grow overnight, approximately 16 hours. Following growth the plasmid is
isolated using Qiagen Mini-prep Kit. At this point it is necessary to check the contents of
the plasmid as there are two possibilities that exist for what may be present based on the
colonies selected, an empty vector, or the vector with the inserted gene. E. coli is known
to take up only one type of plasmid so in theory each colony should be representative of
only one type of the possible products referenced above. To determine the contents of
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the colonies selected, the plasmids are isolated once again using the Qiagen mini-prep kit
and protocol. Using 5uL of the PCR product, add 1 μl of 20 U/ml of both BamH1 and
EcoR1, incubate at 37°C for one hour. Also prepared is a singly cut plasmid using only
BamH1 which produces a single linear stretch of DNA.

A 0.8% agarose gel is then

prepared by adding 0.8g of agarose to 100mL of 1X TAE buffer. When the restriction
enzyme reaction is complete, extract 5µL of the product to 1µL of 6X DNA loading dye
by NE Biolabs and load into the gel. The gel power box is set to run at a constant 95 mA
and run until the dye front reaches to approximately 75% of the length of the gel. A 1
kilobase marker (New England Biolabs) is used as the pGEX vector is 4900 base pairs
and the PHD2 insert is 740 base pairs for a total of 5640 base pairs. If only one band is
present this is representative of only the original plasmid, if two bands are present this is
the plasmid plus the gene. The singly cut plasmid produces a band which aligns between
the markers for 5000 and 6000 base pairs suggesting a product with the correct size for
the plasmid plus the gene. A doubly cut plasmid produces two bands also suggesting the
desired target. With these results the samples require sequencing to confirm the actual
content of the insert in the plasmid.

The samples are prepared for sequencing by

adhering to the protocol listed on the Genewiz.com web site for sample submission.
Once positive sequence results are obtained the process or PHD2 expression is initiated.
PHD2 expression is achieved by growing the transformed PHD2-pGEX in E. coli BL-21
cells that are grown in 2X YTA media (16 g L-1 Tryptone, 10g L-1 yeast extract, 5g L-1
NaCl). Culture volumes of 1.5L of sterilized 2X YTA media containing 100μg ml -1 of
ampicillin are seeded from a 300mL overnight culture with a OD 600 of approximately 1.4
at 1:50 seeding volume and grown at 37°C until a OD600 of .8-1.0 is achieved. Once the
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desired OD reading is achieved the cells are induced with 1mM IPTG (Isopropyl β-D-1thiogalactopyranoside) and the temperature is dropped to 25°C and grown overnight.
The lower temperature facilitates the solubility of GST fusion proteins by slowing down
the folding process allowing more time for confirmation sampling of the lowest energy
confirmations of the protein.

The cultures are then centrifuged and the cell paste

collected for purification. The cell paste is generally frozen for future use and freezing
prior to lysis is required to increase lysis efficiency. The cell paste is lysed with 2mL of
lysis buffer per gram of cell paste. The lysis buffer is the binding/wash buffer of the
MagneGST purification system with EDTA added to a final concentration of 0.5mM.
Lysing in this buffer eliminates the need for a dialysis step after lysis. The lysis buffer
also contains 1mM AEBSF (4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride),
a protease inhibitor, 1mM DTT, 0.5% Triton-X, and 300 µg/mL lysozyme. Lysis is
achieved through sonication until the lysate is non-viscous. The lysate is then centrifuged
at 18,000 G for 30 minutes to remove cellular debris. The lysate is then cleared using a
0.45μm syringe filter in final preparation for loading onto the Promega MagneGST
magnetic purification resin. Once the binding step is completed the resin is washed three
times with wash buffer to remove any non-specifically bound proteins. The protein is
then eluted using 25mM glutathione in 25mM Tris-HCL pH 8. After all protein has been
processed it is loaded into a 10kDa dialysis tube for buffer exchange with PBS pH 7.0.
At this point the solution now contains purified GST-PHD2 fusion protein as confirmed
by SDS-PAGE analysis with bands appearing at approximately 54kDa. To this solution
restriction grade thrombin is added at a final concentration of 0.5 units per mg of fusion
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protein. The volume of the fusion protein solution should be 2 mL for every milligram of
protein requiring GST tag cleavage.
Upon completion of GST tag cleavage which takes 16 hours at 4°C the resulting solution
is passed back through the MagneGST resin to remove the GST tag, followed by a
HiTrap Benzamidine FF column (GE Healthcare) to remove the thrombin as per the
manufacturer’s protocol.

The resulting solution is then transferred to a Vivaspin

centrifugal concentrator to achieve a concentrated solution of pure PHD2, the final
concentration of protein is dependent upon the type of experiments to be performed but
may be concentrated up to 1.5 mM without any aggregation or precipitation. At the same
time as concentration the buffer is exchanged into 50 mM HEPES pH 7.0. Protein purity
is assessed by SDS-PAGE gel and mass spectrometry.

The Oxygen Dependent Degradation Domain (ODDD) Substrate
A synthetic peptide representing a segment of the oxygen dependent degradation domain
(ODDD) of HIF-1α consisting of residues ODDD556-574 DLDLEALAPYIPADDDFQL
was used for all assays, the proline that is hydroxylated is underlined. The ODDD
sequence

is

slightly

modified

from

the

natural

sequence

of

DLDLEMLAPYIPMDDDFQL in which the underlined methonine residues were
replaced with alanine to eliminate possible oxidation products upon mass spectrometry
analysis. These modification ease analysis while not impacting the recognition sequence
of LXXLAP deemed necessary for PHD2 hydroxylation. The substrate is received as a
lyophilized powder and is re-suspended in 50 mM HEPES pH 7.0 or the buffer required
for experimental purposes. Determination of the resulting concentration of peptide is
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achieved by dilution into 0.1 M NaOH and placed in a quartz cuvette for a UV-Vis
reading. In 0.1 M NaOH the singular tyrosine is deprotonated producing a peak at 293
nM. The molar absorbency for deprotonated Tyr is 2400 M -1 cm-1. From this value and
by taking at least five independent aliquots the concentration of substrate is calculated.

FIH Purification and Peptide Substrate
FIH is isolated and purified as previously described89, 90. FIH utilizes a peptide fragment
of the CTAD domain consisting of 39 residues with the following sequence and
containing Asn803, DESGLPQLTSYDAEVNAPIQGSRNLLQGEELLRALDQVN. This
peptide is purchased from EZBiolab’s as a lyophilized powder.

Activity and Inhibition Assays
Activity assays were conducted using 1.5 µM PHD, 2mM ascorbic acid (Acros), 0-500
µM α-ketoglutarate (Acros) and 20µM ammonium iron (II) sulfate (Acros) in HEPES
buffer pH 7.0 (Fisher). A peptide fragment of HIF1-α (ODDD) consisting of residues
556-574 with the sequence of DLDLEALAPYIPADDDFQL and containing the target
proline residue (P564) purchased from GL Biochem (Shanghai) LTD was used for
determination of hydroxylation by MALDI. Assays were conducted at 37°C and time
points were extracted and quenched in a matrix consisting of 4-α-cyano hydroxycinnamic
acid with a 2:1 ration of acetonitrile and 0.2% trifluoroacetic acid. Samples were then
analyzed on a Bruker Daltonics Omniflex MALDI-TOF and the results were interpreted
as a ratio of the parental peak to the hydroxylated peak which exhibits a mass shift of 16
from the parental. A typical raw MALDI-TOF spectra is depicted and labelled below.

31

Figure 2.3 MALDI spectra displaying the peptide (2133 Da) plus a sodium adduct,
followed by additive sodium products. The product peak is labeled as MO+Na, a typical
linear regression resulting from analysis is shown as an inset.
The peptide shows up as the peptide mass (2133 Da) plus a sodium adduct and
subsequent salt peaks representing plus 2Na+, 3Na+ etc. are also detected. Regardless of
which peaks are analyzed the resulting ratios are the same for any given set of peaks. A
typical linear regression from analyzing the MALDI data is show as an inset. Inhibitors
were dissolved in 50 mM HEPES pH 7.0 as were α-ketoglutarate and ascorbic acid. The
inhibitors tested were 3-cyano-6-methyl-2(H) pyridinone (1), 2-hydroxypyridine 1-oxide
(2), 2,3-dihydroxypyridine (3), 5-hydroxy-2-hydroxymethyl-4-pyrone (4), 5-hydroxy-4oxo-4H-pyran-2-carboxylic acid (5), 3-hydroxy-2-methyl-4-pyrone (6), 3-hydroxy-1,2dimethyl-4(1H)-pyridinone (7), 4-nitrocatechol (8), 4-methylcatechol (9), and 4-tert-
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butylcatechol (10). Initial screening of PHD2 was conducted as for activity assays listed
above with the exception of using either 10 μM or 200 μM α-ketoglutarate. Dose
response curves also followed the same guidelines as for activity assays with the
concentration of inhibitor used ranging from 0-1 mM.
UV-Vis Spectroscopy
Solutions of enzyme, iron, buffer and inhibitor were prepared by mixing 30µM PHD2, 25
µM ferrous ammonium iron (II) sulphate and 25 µM inhibitor under anaerobic conditions
in a coy chamber. All mixtures were in 50 mM HEPES buffer at pH 7.0. Data collection
was performed on an Agilent HP8453 in septa sealed cuvettes.

Electroparamagnetic Resonance Spectroscopy (EPR)
X-Band EPR spectra were recorded on a Bruker Elexsys E-500 ESR Spectrometer
equipped with DM4116 cavity, with samples placed in a liquid-nitrogen finger dewar.
Samples were prepared by combining each enzyme with CuSO4 in ratio of 1:0.9 then
adding αKG or inhibitor as indicated. In each of the samples, the CuSO 4 solution was
slowly added in 0.5 μL increments to prevent protein precipitation.
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Results & Discussion

Dose Response to Inhibitors
An initial screen of the inhibitors was tested against PHD2 and FIH to isolate if the
compounds displayed a differential inhibition profile. Each enzyme was screened using
α-ketoglutarate concentrations approximately at the KM which was determined to be, 7.0
± 2.5 µM for PHD2 and KM = 22 ± 6 µM for FIH91. A secondary screen was assayed at
saturating α-KG concentrations as less effective inhibition under these conditions is a
signature for competitive inhibition. The screen indicated that from each chemical class
multiple compounds were able to decrease enzyme activity by 50% or more (Figure 2.4).
Two compounds from the pyrones/pyridinone class and two catechols were effective
inhibitors of PHD2 at sub-saturating α-ketoglutarate concentrations ([ KG] ~ Km). A
similar variety of compounds were effective inhibitors of FIH at sub-saturating

KG.

The non-overlap of inhibitors for FIH and PHD2 strongly suggested that one or more of
these compounds would be selective toward these enzymes.
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Figure 2.4 Initial inhibitor screening. PHD2 assay conditions, 1.5 μM PHD2, 10 or 200
μM αKG, 20 μM ferrous ammonium sulfate, 2 mM ascorbate, 60 μM ODDD and 100 μM
of inhibitor. FIH assay conditions, 0.5 μM FIH, 10 or 500 μM αKG, 500 μM FeCl2 ,
2mM ascorbate, 66 μM CTAD and 100 μM inhibitor. Assays were at 37 °C and time
points extracted and quenched followed by analysis on MALDI for PHD2 and ESI-MS
for FIH. Product formation was calculated by the equation [SubOH] = (Sub-OH) x [Sub]0,
where Sub is CTAD or ODDD respectively. (1) CNP, (2), NOP, (3) DHP, (4) Hop-OH,
(5) Hop-COOH, (6) Hop-Me, (7) HOPO, (8) 4NCat, (9) MeCat, (10) BuCat. FIH
collection by B. Holmes.
It was determined that based upon the initial screening that full dose response curves for
each enzyme would be conducted to isolate their respective IC 50 values, dose response
curves for FIH are not shown but a summary of data is included in Table 2.1 (Figure 2.5).
PHD2 exhibited typical single site binding dose response curves to the majority of the
inhibitors tested with the exception of HOPO (6) and BuCat (10). PHD2 binding to these
compounds resulted in an apparent two-site binding dose response with inflections at 16
nM and 25 µM for HOPO and 50 nM and 50 µM for BuCat. While it cannot be
definitively stated why this result is achieved it is plausible that the inhibitor is binding at
a second metal binding site discovered in PHD2 with an as of yet unknown function92.
The second plausible possibility is that two molecules of inhibitor are binding at the
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active site which has been witnessed in crystallographic studies of FIH in which two
molecules of a hydroxyamic acid analogue bind to the iron, partially displacing the
Asp201 from coordinating the iron93. It is worth recalling at this point that FIH only
requires coordination of the two histidines in order to maintain catalytic activity and
therefore displacement of the aspartate in these two enzymes is a further source for
selective inhibition74.

Figure 2.5 Dose response curves for all inhibitors. Reaction conditions are 1.5 μM
PHD2, 10 μM αKG, 20 μM ferrous ammonium sulfate, 2 mM ascorbate, 60 μM ODDD
and 0-1 mM for each inhibitor.
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The dose-response curves were in agreement with the initial screens and indicated that
compounds from each structural class inhibited FIH and PHD2 with IC50 < 500 μM
(Table 2.1).

Compound
1
2
3
4
5
6
7
8
9
10

PHD2
FIH
IC50 ( M) IC50 ( M)
CNP
NOP
DHP
Hop-OH
Hop-COOH
Hop-Me
Hopo
4NCat
MeCat
BuCat

>1000
3
5
400
30
1000
40*
6
4
30*

>1000
300
200
>1000
400
800
400
6
16
20

Table 2.1 IC50 values for PHD2 and FIH. *For Hop-Me the concentration to achieve
exactly half the maximal rate is 16 µM, for BuCat it is 1.0 µM, the values in the table are
reflective of the second inhibitory event as a two site binding mechanism was witnessed
in PHD2. FIH experiments performed by B. Holmes.
Each of the compounds tested was a more effective inhibitor of PHD2 than of FIH,
reflective of the differences between the two enzymes. This result may also feed back
into the fact that PHD2 exhibits tighter binding constants for iron and αKG 73. In the
pyridine class the trend for both enzymes is the same, NOP≈DHP>CNP. CNP had no
inhibition effect on either Hydroxylase up to 1 mM even though the cyano functional
group is a known metal chelating inhibitor of cytochrome C oxidase. Despite seeing a
similar trend there is an approximate 100-fold preference of NOP toward PHD2 and
similar results are observed for DHP. In the pyrones/pyridinones different trends do
exist. For PHD2 regarding the functional groups of the base compound the preference is
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2Me>COOH>OH>Me while for FIH it is COOH>2Me ≈Me>OH. In this case there is
additional bulk and hydrophobicity provided by HOPO that is clearly favored in PHD2
over the single methyl moiety in Hop-Me while FIH does not distinguish between the
two. The trends in FIH favor the COOH moiety indicating that the functionality of the
carboxy group may provide hydrogen bonding contacts within the active site that are
similar with those of αKG. The conformation of the hydroxyl group of Hop-OH also
poses interesting results as the hydroxy group is able to function as a hydrogen bond
donor/acceptor within the pocket if the fit is acceptable. The IC50 value for PHD2 is half
that of FIH signaling the position and conformation of this moiety is a framework to
build upon. Also of interest in this class of compounds is that the singular methyl moiety
of HOPO generated an IC50 value twice that for PHD2 as for FIH and is the only example
within the compounds where FIH is inhibited over PHD2. HOPO demonstrated a twosite binding mechanism when bound to PHD2 resulting in two inflection points at 21 nM
and 43 μM. The initial response on PHD2 at 21 nM decreases the enzymes activity by
approximately 30% from an activity of 1.0 min-1 to 0.7 min-1. The second inhibitory
event occurs at approximately 43μM with a reduction in rate to 0.3 min -1 equivalent to a
70% overall reduction of rate. The concentration to achieve exactly half the maximal
activity occurs at approximately 16 μM.
This further supports that the second coordination sphere about the iron active site is vital
for purposes of gaining selective inhibition. There is also a much wider range in IC50
values for this class of compounds by more than 400-fold. The IC50 values of the
catechol class support their strong chelating abilities on both enzymes. The relative trend
is that FIH appears to be more tolerant of sterically bulky inhibitors than PHD2 which
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may in part be attributed to their relative pocket sizes mentioned previously. Of interest
is that FIH did not discriminate BuCat from MeCat while PHD2 showed roughly a tenfold difference between the two compounds.
UV-Visible Spectroscopy of Inhibitor Binding
Integral to determining the mode of inhibition is support for the binding of the selected
compounds to the metal center. Inhibitory effects can be the result of multiple reasons
ranging from denaturation, nonspecific binding, precipitation, or aggregation94. The use
of spectroscopy with metalloenzymes can provide evidence to support inhibition is the
result of chelation because of changes in the electronic environment that occur at a metal
center when different species are bound which shift charge transfer bands. For purposes
of this study 4NCat was employed for UV-Vis studies as it exhibits visible absorption
bands and displays shifts in response to deprotonation. 4-Nitrocatechol has also provided
insight into substrate binding and pKa shifts in the catechol dioxygenase family95-97. The
π- π* transition for 4NCat (pKa=6.6, 10.7) is found at 410 nM in Homoprotochaechuate
2,3-dioxygenase, a related enzyme in function possessing an extinction coefficient of
10,800 M-1 cm-1 at pH 7.597.

4NCat in H2O exhibits wavelength and extinction

coefficient shifts representative of its protonation state as the pH is varied. At pH 7.25
λmax= 426 (ε=11,000), pH 8 λmax= 428 (ε=14,700) at pH 12.5 λmax= 383 and 511 (ε=6,300
and 10,400)95. We find that PHD2 and FIH in solution with iron and 4NCat exhibit
results consistent with the binding of 4NCat in the 4NC-1 charge state (Figure 2.6).
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Figure 2.6 PHD2 and FIH in the presence of iron(II) and 4NCat, pH 7.0. Samples were
prepared anaerobically and sealed in cuvettes for data collection.
Control spectra were also collected for 4NCat in the presence and absence of FeSO 4 at
pH7.00 (λmax=427 nM) and pH 12.00 (λmax=515 nM). The (Fe+4NCat)PHD2 spectra
exhibited a λmax of 420 nM and FIH at 428 nM both consistent with a singly deprotonated
4NCat bound to the metal center, for control spectra see Figure 2.7.
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Figure 2.7 Control spectra for 4-Nitrocatechol. Samples were prepared anaerobically at
pH 7 and 12, 4NCat with iron (II) at pH 7, PHD2 at pH 7.
Electroparamagnetic Resonance Spectroscopy (EPR)
Since 4NCat is the only inhibitor which exhibits strong visible bands for the detection of
metal binding, EPR was employed as a secondary measure to support the model of the
inhibitors binding to the iron core.

HOPO was chosen for EPR experiments as it

displayed an inhibitory effect on both enzymes as well as displaying a two-site binding
mechanism towards PHD2. This result in and of itself warrants further investigation of
the compound to support chelation as the mode of binding. Copper (II) was employed as
a probe for both PHD2 and FIH as iron(II) is ERP silent due to the lack of an unpaired
electron. The results are indicative of HOPO binding the iron in both enzymes, and not
simply a result of binding free metal in solution as can be observed from the spectral
changes (Table 2.2, Figure 2.8).

For each enzyme in the presence of copper the

magnitude of gII and AII provide significant information regarding the electronic changes
centered about the metal as they are dependent upon the ligand environment. In essence
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if the ligand is changed from αKG to HOPO and no changes are detected in gII and AII,
after factoring in all the controls, then the inhibitor is not binding to the metal.
Detectable changes in these parameters upon ligand substitution assure that binding is
occurring at the metal active site.
EPR Parameters
gII

g

AII (G)

(CuSO4)

2.28

2.07

161.3

(Cu+αKG)

2.28

2.08

143.4

(Cu+HOPO)

2.28

2.06

164.1

(Cu+HOPO)PHD 2.32

2.07

145.1

(Cu+αKG)PHD

2.35

2.07

141.6

(Cu)PHD

2.29

2.06

147.9

(Cu+HOPO)FIH

2.33

2.07

136.7

(Cu+αKG)FIH

2.35

2.07

138.1

(Cu)FIH

2.28

2.06

152.1

Table 2.2 EPR Sectral parameters for (Cu)FIH and (Cu)PHD2. Parameters were
determined using Spincount.

The spectral features of (Cu)PHD2 and (Cu)FIH share many similarities as can be
expected based on their 2-His1-Asp facial triads. There is also no witnessing of any
observable fine structure detail that would be consistent with splitting from the protein
derived ligands. Both the (Cu)FIH and (Cu)PHD2 display four relatively weak hyperfine
splitting features as a result of binding to Cu(II).

However, the addition of the anionic

αKG ligand in conjunction with Cu(II)PHD2 caused these hyperfine features to become
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well resolved (Figure 2.8). The addition of this ligand generates increases in the gII and
decreases in AII values as would be expected upon metal binding98. The values for FIH
are in agreement with previously reported values 99. To determine the mode of binding
and determine if the inhibitors were binding at the active site HOPO was employed for

Figure 2.8 X-Band EPR spectral changes upon Hopo binding to FIH and PHD2. FIH
(0.65mM), CuSO4 (0.60mM), αKG (0.60mM), HOPO (0.60mM) in 50mM HEPES pH
7.50. 9.615 GHz frequency, 5 mW power, 5G modulation amplitude, 100 GHz
modulation frequency, 20ms time constant at 100 K. PHD2 (0.65mM), CuSO4
(0.60mM), αKG (0.60mM), HOPO (0.60mM) in 50mM HEPES pH 7.50. 9.598 GHz
frequency, 5 mW power, 5G modulation amplitude, 100 GHz modulation frequency,
20ms time constant at 100 K.

the EPR studies. The (Cu + HOPO) spectra exhibited hyperfine splitting that was similar
to the (Cu)FIH and (Cu)PHD spectra with geff (g = 2.06, and gII = 2.28) and a slightly
larger hyperfine coupling value (AII = 164.1G). However, there is additional resolvable
hyperfine coupling in the g region of the (Cu + HOPO) spectra. These additional
resolvable hyperfine features are diminished in the (Cu + HOPO)FIH and (Cu +
HOPO)PHD2 spectra, indicating that there is a difference in ligand coordination and
possibly geometry in the presence of enzyme. There is also an increase in anisotropy
43

similar to that observed for the addition of αKG with g eff (g = 2.07, and gII = 2.33) for
(Cu + HOPO)FIH and geff (g = 2.07, and gII = 2.32) for (Cu + HOPO)PHD2.
Additionally both (Cu + HOPO)FIH and (Cu + HOPO)PHD2 show decreased hyperfine
coupling compared to the (Cu + HOPO) spectra, suggesting the presence of an anionic
ligand interaction with Cu(II). The changes in electronic structure indicate that Cu(II) is
being incorporated at the active sites of both PHD2 and FIH, and that HOPO is binding to
the copper at the active site. This strongly denotes that the main mechanism of inhibition
is through chelation of inhibitors at the active site to the Fe(II) rather than sequestering it
from the enzyme through chelation in solution.

Conclusions
The catalytic activity of the HIF hydroxylases in this study is perturbed by the chelating
ability of the selected inhibitors. While these compounds do not exhibit a definitive
selectivity between PHD2 and FIH, they do hint at the possibility that the internal binding
pocket of each enzyme which has marked variation can be exploited to further this cause.
Both FIH and PHD2 share a similar active site with a 2His-1Asp facial triad and but they
do exhibit differences in the hydrogen bonding networks within the enzyme core. The
contacts made between active site residues and α-KG within both enzymes provide key
contacts in which it may be possible to build selectivity. Exploration of the key residues
within the active site of each enzyme reveal that PHD2 utilizes Arg 383 and Tyr329 from a
core DSBH to bind to the 5-carboxylate of α-ketoglutarate while FIH employs Lys214 and
Tyr145 which does not stem from a DSBH. These residues interactions with the inhibitors
may be a contributing factor to the differences seen in the IC50 values especially amongst
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the inhibitors of the pyrones/pyridinones class which displayed differences in the overall
trends of binding with PHD2 showing preference towards the dual methyl moiety versus
FIH’s preference toward the carboxylate moiety. In lieu of the results that most of the
inhibitors preferentially inhibited PHD2 over FIH with the exception of HOPO it is not
unreasonable to assume that much of this difference can be attributed to potential steric
clash from specific FIH residues. For example, FIH Gln147 projects into the active site
pocket to within 5 Å of the αKG 5’carboxylate position, the equivalent residue in PHD2
is Ala301, a far less obtrusive residue (PDB 1H2M, 3HQU respectively). Overall the
pyridine/pyridinone class of inhibitors show promise for further elaboration in the
development of selectivity toward the HIF hydroxylases. These compounds displayed
substantial variation in IC50 values reflective of changing functional groups and bulk.
The catechols as a whole proved to be potent inhibitors exemplative of the strong
chelating ability associated with this class and their subsequent derivatives. Of notable
interest in this class is BuCat which displayed a two-site binding mechanism with PHD2
with the initial inhibitory event occurring at 41 nM equating to a 20% reduction in rate
and a secondary inhibitory event at 32 µM and a 80% reduction in the rate with the actual
IC50 occurring at approximately 1 µM. FIH showed a standard one-site binding mode
with an IC50 of 20-fold to that of PHD2. This may partially be explained by the size of
the binding pockets of each enzyme, while FIH does possess and overall larger pocket it
is shallower in comparison with that of PHD2 and the bulky tert group cannot be
accommodated to the same extent, providing further scaffolding for future design of
inhibitors. While the pyridine class of compounds tested did not display any relative
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differences in trends amongst them it is notable to mention that there is an approximate
100-fold preference of NOP toward PHD2 and similar results are observed for DHP.
In short we find that the pyrone/pyridinone class of chelates to be promising for further
development of selective inhibitors for the HIF hydroxylases. The formation constants
for this class towards 2+ transition metals are modest and it is very likely that the IC 50
values reflect structural differences between the two enzymes. As HOP-Me, aka maltol
has been used as a foundation for inhibitors of matrix metalloproteases, basing further
inhibitors on this framework may lead to increasingly potent selective compounds for
PHD2 and/or FIH.
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MECHANISTIC STUDIES INVOLVING pH AND SOLVENT ISOTOPE
EFFECTS ON PHD2
Introduction

The study of enzyme-catalyzed reactions under the influence of pH can provide
information regarding the underlying kinetic and chemical mechanisms.

With the

introduction of solvent isotope effects (SIE), even greater information about the chemical
mechanism via identifying isotope-sensitive steps may be obtained. Solvent isotope
effects can be observed when enzyme catalyzed reactions are measured in equivalent
buffers based in either H2O or D2O. The SIE arises as a result of the different physical
properties of H2O and D2O, which include greater density and viscosity as well as
stronger hydrogen bonds, all of which can impart changes in protein-substrate
interactions as hydrogen is exchanged for deuterium. The impacts of D2O have the
potential to affect enzyme stability, conformational change, and substrate binding as well
as the kinetic and equilibrium constants associated with the overall reaction and care
needs to be taken to execute proper controls before final analysis is complete. The SIE is
deemed as a global effect since substitution occurs at multiple sites versus substrate
isotope effects in which one or only a few positions are substituted. Ultimately the SIE is
measured as a ratio of the reaction in water to the reaction in deuterium100, 101. When the
kinetic parameters kH/kD, VH/VD or (V/K)H/(V/K)D are larger than unity (larger in H2O) a
normal solvent isotope effect is observed. When the parameters are less than unity (larger
in D2O), it is called an inverse solvent isotope effect.
Inverse solvent isotope effects only arise under certain circumstances and are rarely
reported and therefore they can be highly diagnostic of underlying chemical mechanisms.
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An inverse SIE can be attributed to the acid dissociation constant of a thiol, a diffusionsensitive conformational change arising from solvent viscosity effects, or the dissociation
of a metal-chelated water102-105.
While it is noted that studying enzyme-substrate reactions at arbitrary substrate
concentrations may prove useful they also can have decreased value. This is the result of
the fact that the steady-state rate of the reaction encompasses all of the pKa values of the
entire kinetic system which includes free enzyme, substrate, intermediates and complexes
formed. However, what can be gained from these studies is the pH dependence of the
catalytic constant kcat, which unveils pKa values for certain enzyme-substrate complexes
or intermediates and provides the specificity constant kcat/KM. When pH studies are
combined with SIE a broader spectrum of information may be obtained about the overall
system under investigation.
When considering the complete catalysis of PHD2 involving kcat and KM the focal point
are the steps after αKG and substrate have bound and the enzyme is primed for oxygen
activation. At this junction the enzyme should be in a five coordinate state with one
water ligand still in place, if only briefly. A general scheme for the kinetic parameters
believed to be involved in the mechanism of PHD2 is shown in (Figure 3.1).
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Figure 3.1 Catalytic steps involved in PHD2 catalysis. Focus is upon the first
irreversible step when oxygen is activated denoted by the kcat arrow.
Methods and Materials

Mixed Buffer Preparation of MES-PIPES-HEPES (MPH)
A mixed buffer solution of MES hydrate (2-(N-morpholino)ethanesulfonic Acid) from
Sigma, PIPES (1,4 – Piperazine Diethane Sulfonic Acid from Fisher Biotech, and HEPES
(4-(2-Hydroxyethyl)-1-Piperazineethanesulfonic Acid from Fisher Scientific (MPH) was
prepared consisting of 20 mM of each buffer to avoid changing buffers to study the full
range of pH thereby eliminating any effects from the buffer alone. A 200 mL solution of
60mM MPH buffer, consisting of 20 mM MES, 20 mM PIPES and 20 mM HEPES was
made and divided in two. One half of the buffer was brought up to a pH of 8.88 by the
addition of 1M NaOH and the ionic strength was calculated, this buffer is deemed the
base form. The ionic strength at 37°C was calculated for each buffers contribution by
using a ‘buffer calculator’ (www.biomol.net/en/tools/buffercalculator.htm), the ionic
strength of the NaOH that was added to produce the base form of the buffer was then
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calculated based upon the equation,

I

1 n
ci zi2 .
2i 1

The final ionic strength was determined

to be 130 mM for the base form. To the acid form of the MPH buffer which has a pH of
5.8, NaCl was added as a solid to match the ionic strength of the base form at 130 mM.
These two solutions of buffer of identical ionic strength were then mixed at various ratios
to achieve a range of pH without any variation of the ionic strength. MPH buffer was
also prepared exactly as listed above except D2O was substituted for H2O to dissolve all
buffer components and NaOH was dissolved in 99.9% D2O to pD the base from of the
buffer. These buffers were used for all solvent isotope experiments. For all D2O buffer
preparation, the pH electrode was equilibrated in D2O for 30 minutes prior to measuring
the actual pD of the full range of prepared buffers, and applying the equation of pD = pH
+ 0.4.

Protein and Solutions Preparation for pH and SIE Experiments
Aliquots of PHD2 were diluted to a final concentration of 7.5 µM in either the
appropriate 60 mM MPH buffer of H2O or D2O as dictated by the current experiment.
The pD of deuterated buffers was calculated by the following equation, pD=pH + 0.4.
The resulting dilutions of PHD2 in D2O buffer contain a final concentration of 97.87%
D2O, 1 µL of this stock is placed in 24 µL of a 99.9% D2O component mixture for all
reactions resulting in a 97.82% deuterated buffer. All stock solutions of ascorbic acid, αketoglutarte, iron and ODDD were prepared in either H2O or D2O as dictated by the
experiment. All assays for both H2O and D2O work were conducted using 0.3 µM
PHD2, 15 µM ferrous ammonium sulfate, 1 mM ascorbic acid and 200 µM αketoglutarte. For all kinetics experiments, the substrate, ODDD was varied between 1-50
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µM. All components of the reaction were mixed and initiation of the experiment was
induced by the addition of ODDD. Time points were extracted and quenched in a
MALDI matrix consisting of 4-α-cyano hydroxycinnamic acid with a 2:1 ration of
acetonitrile and 0.2% trifluoroacetic acid. Samples were then analyzed on a Bruker
Daltonics Omniflex MALDI-TOF and the results were interpreted as a ratio of the
parental peak to the hydroxylated peak which exhibits a mass shift of 16 from the
parental peak.

UV-Visible Spectroscopy
Acid and base forms of PHD2 were prepared anaerobically in a coy chamber by mixing
50 µM PHD2 with 45 µM ferrous ammonium sulfate and 50 µM αKG into fully degassed
MPH buffer at pH 6.5 or pH 8.5 respectively. The cuvettes were sealed with septa and
analyzed on a Agilent HP8453 to determine if any spectral changes between the two
samples could be elucidated. The spectra were then evaluated by subtraction of the pH
6.5 from pH 8.5.
X-Ray Absorbtion Spectroscopy
Sample preparation for analysis by XAS was prepared anaerobically in a Coy chamber by
mixing 1 mM PHD2, 0.9 mM ferrous ammonium iron (II) sulphate and 0.9 mM αKG in
60 mM MPH buffer at pH 6.5 for the acid form of the enzyme and pH 8.5 for the base
form. Both samples were initially brought up to a volume of approximately 500 µL with
their respective buffers for the addition of iron and αKG and subsequent incubation for
15 minutes. Samples were then treated with CheleX® to remove all unbound metal from
the samples for 30 minutes. After the incubation time to remove excess unbound iron the
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samples were then concentrated to a final volume between 40-50 µL resulting in the final
concentrations listed above. Samples were then loaded into a XAS sample holder and
immediately submerged in liquid N2 in the evacuated anti-chamber of the Coy chamber
and transferred to -80°C until sample analysis could be performed. XAS data collection
and analysis were performed as reported previously106. X-ray absorption near edge
spectroscopy (XANES) data was collected from -200 eV to +200 eV with respect to the
Iron edge energy (7111.2 eV). Extended X-ray absorption fine structure (EXAFS) data
was collected to k = 14 Å-1 above the edge energy. Data was fit using FEFF software
which provides for the calculation of phase shifts and effective scattering amplitudes of
polarization dependent single and multiple scattering X-ray Absorption Fine Structure
(XAFS) and X-ray Absorption Near-Edge Structure (XANES) spectra for clusters of
atoms.

Viscosity Test
PHD2 was assayed in 50 mM HEPES D2O buffer at pH 7.0 by mixing 0.3 µM PHD2, 1
mM ascorbate, 15 µM ferrous ammonium sulfate and 200 µM αKG all prepared in D2O
and initiating the reaction with 15 µM ODDD. The identical assay was also performed
by adding 10% sucrose to a non-deuterated 50 mM HEPES pH 7.0 buffer to mimic the
viscosity imposed by D2O to exclude viscosity as the underlying factor observed in the
rate differences. The relative viscosity (η/ηo) of D2O at 37°C is 1.31 mPa*s. The relative
viscosity of a 10% sucrose solution at 20°C is 1.333 and at 37°C it is approximately 1.3
mPa*s and therefore approximates the viscosity of D2O107. Assays were conducted at
37°C and time points were extracted and quenched in a matrix consisting of 4-α-cyano
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hydroxycinnamic acid with a 2:1 ration of acetonitrile and 0.2% trifluoroacetic acid.
Samples were then analyzed on a Bruker Daltonics Omniflex MALDI-TOF and the
results were interpreted as a ratio of the parental peak to the hydroxylated peak which
exhibits a mass shift of 16 from the parental.

Stability Assays
PHD2 stability was assessed by incubating the enzyme at various pH’s for 15 minutes
prior to the initiation of the assay. As standard linear rates are collected within five
minutes a fifteen minute incubation was more than appropriate. After the incubation time
the enzyme was mixed as 0.3 µM PHD2, 15 µM ferrous ammonium sulfate, 200 µM
αKG, 1.0 mM ascorbic acid and the assay was initiated with 15 µM ODDD in a three
component buffer of 60 mM MPH at pH 7.0 and the collection of linear data was
complete within approximately four minutes for all assays. Assays were conducted at
37°C and time points were extracted and quenched in a matrix consisting of 4-α-cyano
hydroxycinnamic acid with a 2:1 ration of acetonitrile and 0.2% trifluoroacetic acid.
Samples were then analyzed on a Bruker Daltonics Omniflex MALDI-TOF and the
results were interpreted as a ratio of the parental peak to the hydroxylated peak which
exhibits a mass shift of 16 from the parental.

Incubation Assays
Incubation assays were conducted to determine if PHD2 was able to regain full activity
after exposure to a pH which resulted in the reduction of initial rate. PHD2 was exposed
to 60 mM MES,PIPES, HEPES buffer at pH 8.5 which is out of the stability range for 15
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minutes. The enzyme was then reintroduced to a 60 mM MPH buffer at pH 7.0 and the
initial rate date collected via time point quench aliquots. Final assay concentrations are
as follows, 0.3 µM PHD2, 15 µM ferrous ammonium sulfate, 200 µM αKG, 1.0 mM
ascorbic acid and the assay was initiated with 15 µM ODDD. Assays were conducted at
37°C and time points were extracted and quenched in a matrix consisting of 4-α-cyano
hydroxycinnamic acid with a 2:1 ration of acetonitrile and 0.2% trifluoroacetic acid.
Samples were then analyzed on a Bruker Daltonics Omniflex MALDI-TOF and the
results were interpreted as a ratio of the parental peak to the hydroxylated peak which
exhibits a mass shift of 16 from the parental.

Data Fitting
All data was fit with OriginPro software using either a simple liner regression for initial
rate data or fitting to the Michaelis-Menten equation. H2O and D2O data was fit to the
following equation to ascertain the actual pKa for each data set where enzH is the fully
protonated

k cat

form

enzH *10[ H
10[ H

]

]

of

the

enz *10
10

pKa

enzyme

and

enz

is

the
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form

pKa

.

Results & Discussion

pH Dependence of PHD2 Catalyzed Hydroxylation of HIF-1α
In an effort to identify catalytically relevant steps and gain a better understanding of the
hydroxylation mechanism of PHD2 we measured the kinetic parameters kcat ,KM and kcat
/KM as a function of pH over the pH scale from 5.80 to 8.88. It was determined that
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activity and potential stability issues arise under pH 6.30 and therefore data that falls
under this pH was not considered in the final analysis.

These experiments were

conducted in a three component buffer of 60 mM MES, PIPES and HEPES to avoid
buffer dependent results and also as a method of controlling the ionic strength by mixing
acid and base forms of the buffer to obtain a full range of pH for H 2O buffers. All data
was fit to the Michaelis-Menten equation, after initial rate data was calculated from
MALDI analysis of the modified substrate (Figure 3.2).
calculated using the equation [ODDDOH] =

(ODDD-OH)

Product formation was

x [ODDD]0 and subsequently fit

using a linear regression to obtain all initial rate information. All data was linear over the
allotted collection time.
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Figure 3.2 Kinetic fits for PHD2 at varied pH. All assays include 0.3 µM PHD2, 15 µM
ferrous ammonium sulfate, 200 µM αKG, 2 mM ascorbic acid and ODDD concentrations
from 0-80 µM. Product formation was calculated using the equation [ODDDOH] =
(ODDD-OH) x [ODDD]0. All data was fit using the Michaelis-Menten equation.

The collection of the kinetic parameter kcat /KM proved to be troublesome due to the very
low KM value for the ODDD (Table 3.1). This value is in the approximate range of 1.02.0 µM in the biologically relevant pH scale with a decline in the KM detected beginning
at pH 8.03. Current detection methods for the substrate do not allow for substrate
concentrations that fall below 1.0 µM in the reaction vessel as extracted aliquots are
minimally diluted and quench into a MALDI matrix for data collection.
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The

concentration of substrate as the instrument detects it is 0.5 µM, this low concentration is
difficult to detect and while peaks are visible the signal to noise ratio tends to be high.
This fact excludes the ability at the current time to reduce ODDD concentrations which
would allow for a more accurate measurement of the true KM. In lieu of this the kcat /KM
appears somewhat random and values above pH 8.03 are unreliable as all data as
analyzed produce initial rates which were equivalent at all substrate concentrations.

kcat, min-1

KM µM

kcat /KM, µM-1min-1

pH 6.32

2.64 ± 0.09

0.60 ± 0.28

4.40 ± 2.06

pH 6.45

2.61 ± 0.09

3.13 ± 0.69

0.79 ± 0.17

pH 6.62

2.37 ± 0.11

1.79 ± 0.69

1.32 ± 0.51

pH 6.95

2.05 ± 0.08

1.77 ± 0.72

1.16 ± 0.47

pH 7.20

1.87 ± 0.09

0.61 ± 0.46

2.75 ± 2.08

pH 7.40

1.41 ± 0.08

0.73 ± 0.46

1.93 ± 1.22

pH 7.64

1.04 ± 0.02

1.57 ± 0.03

0.68 ± 0.06

pH 7.85

0.98 ± 0.04

0.04 ± 0.09

24.3 ± 54.6

pH 8.03

0.60 ± 0.01

1.53 ± 0.21

0.39 ± 0.05

pH 8.25

0.51 ± 0.02

1.23 ± 0.31

0.42 ± 0.11

pH 8.5

0.57 ± 0.02

0.65 ± 0.17

0.87 ± 0.23

pH 8.88

0.46 ± 0.02

0.18 ± 1.12

2.56 ± 15.9

Table 3.1 Kinetic parameters for PHD2 under different pH values
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Figure 3.3 The kinetic parameters kcat /KM and KM for PHD2.
Using the observed kcat values the data was then plotted and fit to determine the pKa
according to the equation, k cat

enzH *10[ H
10[ H

]

]

enz *10
10

pKa

pKa

(Figure 3.3).

Figure 3.4 The PHD2 kcat data fit to determine the pKa of 7.22 ± 0.03.
The kcat parameter unlike that of KM displayed a more systematic decline with increasing
pH generating viable kinetic data. However in the pH range of 6.32 to 8.03 the KM
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remains fairly constant (Figure 3.3) and in an effort to obtain a more viable value for
kcat/KM the average was taken and used to calculate a secondary approximation of kcat/KM.
This secondary approximation was achieved by the application of statistics to the
observed KM values to obtain a singular value with propagated errors (Table 3.2).

pH

kcat/KM, µM-1min-1
Using Averaged KM

6.32

2.06 ± 1.48

6.45

2.04 ± 1.47

6.62

1.85 ± 1.33

6.95

1.63 ± 1.17

7.20

1.46 ± 1.05

7.40

1.10 ± 0.79

7.64

0.81 ± 0.58

7.85

0.76 ± 0.55

8.03

0.46 ± 0.33

Table 3.2 Estimated kcat/KM after statistical analysis on the range of KM’s from original
data set, final estimated KM = 1.28 ± 0.92 µM. The estimated KM was then used with the
experimentally determined kcat to generate the kinetic parameter kcat/KM.
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Figure 3.5 Revised kcat/KM after application of an averaged KM value indicating a
decreasing specificity constant with increasing pH.
While it is herein acknowledged that it would be preferable to have more sensitive
detection methods in which to accurately pin-point the KM values at each particular pH,
the original data set is highly suggestive of the trend observable in the revised kcat/KM
data, as the KM does not significantly change across a range of pH. The lack of changing
KM values is also suggestive that substrate binding may be factored out of the equation
with reference to the observable differences for kcat.
The overall observed pH dependence of PHD2 also has comparisons in other related
enzymes like TauD. TauD is an α-KG, Fe(II) dependant dioxygenase enzyme that when
tested across a pH range of 4.5-10.8 was found to have a maximal activity at pH 6.9,
similar to that found for PHD2108. Procollagen-proline dioxygenase, an enzyme very
closely related to PHD2 exhibits a maximal activity at pH 7.8 for the coupled reaction of
α-KG decarboxylation to peptidyl hydroxylation, but no pH dependence for the
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uncoupled reaction109.

These examples provide support that the witnessed pH

dependence of PHD2 is not an anomalous event.

Stability versus Activity of PHD2
The optimal pH for PHD2 activity was found to be within 6.5-7.0. The stability of PHD2
was assayed and found to be stable in the range of 6.30 to 7.60 with a sharp drop in
stability occurring between 7.60 and 7.80. However, when stability is compared against
activity it appears that the drop in activity which is far more steep of a decline may not
necessarily be associated with a loss of structure (Figure 3.6).

Figure 3.6 Effect of preincubation on the activity of PHD2. All assays include 0.3 µM
PHD2, 15 µM ferrous ammonium sulfate, 200 µM αKG, 2mM ascorbate and 15 µM
ODDD. For stability curve PHD2 was incubated at pH 8.5 and assayed at pH 7.0. For
activity curve PHD2 was incubated at each individual pH and assayed at the same pH as
for incubation. Both curves have been normalized to activity at pH 6.5.
It is plausible that the stability results depicted in figure 3.5 arise from the H2O ligand in
the sixth coordination site being replaced by OH as the pH increases. The hydroxyl bond
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is shorter and stronger than the iron(II)-H2O bond and may not displace as easily on
substrate binding as does the water-ligand (Figure 3.7).

Figure 3.7 PHD2 with either water or hydroxyl coordinated at the sixth position just
prior to ODDD binding.
The iron-water bond length in PHD2 based on PDB 2G19 without substrate bound is 2.09
Å, as a comparative example for the change in bond lengths associated with the exchange
of water for a hydroxyl we can look to a related enzyme system, SyrB2, a non-heme,
αKG-dependent halogenase. The underlying chemistry of this related enzyme employs
virtually the same consensus mechanism as PHD2 except the end result is a halogenation
reaction and not a hydroxylation. The measured bond lengths of the iron-water bond in
SyrB2 is 2.10 Å with a bond dissociation energy of 6.0 Kcal/mol, and the bond length for
the hydroxyl form is 1.88 Å with a dissociation energy of 52 Kcal/mol110, 111. It should be
noted that the hydroxyl form of SyrB2 if for the Fe(III) form, not Fe(II) and relevant
Fe(II)-OH bond length information for similar enzymes could not be obtained. It is not
unreasonable based on the similarity of the iron-water bond lengths in both enzymes that
the shift to iron-OH form in PHD2 would result in a similar shortened bond length and
greater dissociation energy, thereby making less readily available the empty coordination
site necessary for oxygen activation to occur.

Stability assays were conducted by

incubating PHD2 across the pH spectrum and assaying at pH 7.0, while activity assays
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were conducted in each individual pH of the selected range. Since the stability and
activity assays are conducted in a similar manner the fact that the activity falls far below
the estimated stability gives this notion further validity along with the results that support
activity begins to sharply drop off at pH 7.2, well within the stability range which does
not decline until at least the pH 7.6 mark is reached.

Incubation Assays: Determining if Full Activity of PHD2 is Recoverable
To determine if the activity loss of PHD2 which begins to occur at approximately pH 7.2
is recoverable, incubation assays were conducted. PHD2 was incubated in 60 mM MPH
buffer at pH 8.5 and then reintroduced into pH 7.0 buffer followed by initial rate
experiments. PHD2 regains full activity upon reintroduction to pH 7.0 buffer within
minutes of the exchange (Figure 3.8). This strongly suggests that the resulting loss of
enzymatic activity is not due to a complete obliteration of structure and is more likely an
effect attributable to the changing pH and iron-ligand environment especially since
activity begins to drop within the pH range deemed stable. Considering the observed pKa
of 7.32 ± 0.01 is in the expected range for a metal-OH being protonated to form a metalOH2, this is further support for iron-aquo ligand being responsible for the sharp decrease
in activity versus loss of catalytic ability due to enzyme stability112.
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Figure 3.8 PHD2 Incubation assay to determine activity recovery. All assays include 0.3
µM PHD2, 15 µM ferrous ammonium sulfate, 200 µM αKG, 2mM ascorbate and 15 µM
ODDD. Assay time range, 1.4-30.0 minutes. PHD2 was incubated at pH 8.5 and assays
were conducted at pH 7.0.
Following all control experiments with regards to the results of determining the kinetic
parameters for PHD2 which indicated a titratable pKa at 7.32 ± 0.02 determined by fitting
the data to the following equation:

k cat

enzH *10[ H
10[ H

]

]

enz *10
10

pKa

pKa

Equation 1 Where enzH is the fully protonated form of PHD2, and enz is the
deprotonated form.
The fully protonated form of PHD2 displayed at kcat of 2.72 ± 0.01 while the fully
deprotonated from has a kcat of 0.30 ± 0.02.

To further investigate these results

particularly with regards to the iron-ligand environment of PHD2 at a higher pH range
UV-visible spectroscopy experiments were initiated to explore if any difference in their
spectra at different pH’s could be detected.
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Acid and Base Forms of PHD2
Two samples of PHD2 were prepared identically with the exception of the chosen pH of
the solution and prepared anaerobically in a Coy chamber in an effort to maintain the
Fe(II) state.

Many related αKG-dependent dioxygenases display changes to their

coordination environment about the iron in approximately the 500 nM range upon
binding of varying cofactors attributable to a ligand-to-metal charge transfer (MLCT).
These transitions are witnessed in FIH(FeII+ αKG) at 500 nM, Taurine Dioxygenase
(TauD) at 530 nM and in Clavaminate Synthase 2 (CS2) at 476 nM99,

113, 114

. In the

PHD2 difference spectrum (pH 8.5-pH6.5), we see a broad absorption feature with at λmax
at 485 nM, comparable to CS2 and another prominent feature at 342 nM which likely
reflects a shift in the charge transfer bands (Figure 3.9).

Figure 3.9 pH 8.5 and pH 6.5 forms of PHD2. Samples include 50 µM PHD2, 45 µM
ferrous ammonium sulfate and 50 µM αKG. Samples were prepared anaerobically in a
Coy chamber to maintain the Fe(II) state. The resulting spectra is obtained as a
difference spectra, (pH 8.5-pH6.5).
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The two samples at pH 6.5 and pH 8.5 exhibit differences with respect to the
coordination environment of the iron and are likely to be the result of deprotonation of
the iron-OH2 ligand as there are no other variances between the two samples. The red
shift observed at 350 nM may be attributed to the removal of a proton from the pH 8.5
sample which will result in electron destabilization and a shift to higher energy. All
controls were prepared as the samples and do not give rise to the features exhibited when
PHD2 is present.
X-Ray Absorption Spectroscopy
X-Ray absorption spectroscopy can provide several viable pieces of information
regarding the ligand environment as it pertains to the local electronic and or geometric
structure about a metal ion. From the x-ray absorption near edge region (XANES) of the
spectra the coordination number of the metal can be ascertained. From the extended xray absorption fine structure (EXAFS) radial distances of the ligands and the type of
ligands, specifically nitrogen, oxygen and sulfur can be determined (Figure 3.10).

Figure 3.10 XAS regions for determining local geometric and/or electronic environments
about a metal ion. Figure courtesy of N. Giri.
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Upon analysis of the PHD2 (FeII + αKG) form of the enzyme it should be possible to
distinguish the nitrogen atoms from the coordinating histadines, the αKG oxygens, the
aspartate oxygen, and if present the aquo-ligand and/or the hydroxyl ligand which would
be distinguished by its shorter radial distance from the iron. The actual assignment of the
ligands whether they are imidizole nitrogens or oxygens comes from data fitting analysis
which will disallow an improper assignment that will be obvious via skyrocketing
reduced chi-square values (χ2). Ideally, when assigning ligands there should be at least a
30% reduction in the reduced χ2 from the original data to support proper ligand
assignment115.
Two samples were prepared for X-ray absorption spectroscopy (XAS) as previously
prepared for UV-Vis experiments of the acid and base forms of PHD2 with respect to the
pH of the solution.

Figure 3.11 Iron K-Edge XANES sprectra; (Fe2+:αKG:PHD2) at pH 6.5 (red), and pH 8.5
(black)
For the data collection shown in figure 3.11, eight scans were averaged for the
Fe2+:αKG:PHD2 at pH 6.5 and twelve scans were averaged for Fe2+:αKG:PHD2 at pH
8.5. The intensity of the peak associated with a 1s  3d electronic transition was then
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used to indicate the coordination number/geometry of metal sites116,

117

. For EXAFS

analysis of the data collected at the iron K-edge, a limit of 2 – 12 Å-1 was used.
Structural models of the metal sites involving coordination numbers from 2 - 7 were
systematically evaluated for all possible combinations of N/O- and S-donors by holding
the number of scattering atoms in each shell to integer values. The number of histidine
imidazole ligands involved in the coordination sphere was estimated by multiplescattering analysis as previously described118-120. The amplitudes and phase shifts for
multiple scattering paths of the iron-imidazole ligands were generated using FEFF (v.
8.0) with the coordinates of an iron-imidazole ligand obtained from the crystal structure
of human PHD2 with Fe(II) and αKG (3OUJ). Scattering paths of similar length were
combined in one shell, as described by Costello et.al.,119, 120. During the fitting process,
coordination numbers were constrained to be integer values and a scaling factor of 0.9
was used. Bond lengths, σ2 and a single value of ΔE0 were allowed to vary in each fit.
The best iron-imidazole models were further examined using multiple-scattering analysis
derived from the rigid O-C-C-O five-membered chelate rings with parameters obtained
using FEFF (v. 8.0). In this analysis, distances in the chelate ring were constrained to
vary with a single value of r.
To compare different models (fits) the R-factor and reduced

2

parameters can be

assessed, in which case both parameters should be minimized. Although R will always
improve with an increasing number of shells (adjustable parameters), reduced

2

will go

through a minimum and then increase, indicating that the model is over fitting the data.
Best fits were judged by using two goodness of fit parameters, reduced χ2 and R, and the
deviation of σ2 from typical values (table 3.3).
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Sample

____XANES Analysis___

Fe(PHD)-αKG
pH 6.5

Fe(PHD)-αKG
pH 8.5

at

at

Edge
E(eV)

1s3d
peak area
(x10-2 eV)

Coord.
No.

7121.2(2)

8.7(8)

5

7120.9(2)

7.9(4)

5

__________EXAFS Analysis_________
Shell

r (Å)a

σ2b
(x103 2
Å)

4 N/O

2.07(6)

6(4)

2 N/O
(2 Im)

2.19(4)

4(3)

2 N/O

2.05(6)

6(1)

2 N/O
(2 Im)

2.21(5)

6(4)

1O

[2.03(8)]d

7(1)

1O

[2.24(8)]

1C

[2.75(8)]

1C

[2.85(8)]

4 N/O

1.96(3)

5(4)

2 N/O
(2 Im)

2.12(2)

3(2)

3 N/O

2.15(2)

4(2)

1 N/O
(2 Im)

1.96(4)

6(3)

1O

[1.90(6)]

9(3)

1O

[2.11(6)]

1C

[2.62(6)]

1C

[2.72(6)]

ΔE0
(eV)

%Rc

-11 (4)

12.23

9.94

-4(3)

6.43

6.74

-14 (3)

10.65

3.78

-9(1)

5.86

2.67

Table 3.3 XANES and EXAFS analysis of Fe2+:αKG:PHD2 at pH 6.5 and 8.5. ar (Å) is
the radial distance between metal and ligand. bσ2 is the root mean square disorder in the
metal-ligand distance. cR is the goodness of fit. Numbers in parentheses represent
standard deviation for least square fits. d Distances in [ ] correspond to atoms in a O-C-CO chelate ring and were constrained to vary with a single value of Δr for the chelate ring.
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Red.
χ2

XANES Analysis
XAS experiments of PHD2 bound to iron and α-ketoglutarate at pH 6.5 and 8.5 were
investigated to determine data about the coordination number and geometry of the metal
center. XANES data indicates that Fe(II) has vacancies in the 3d manifold that give rise
to peaks associated with 1s  3d electronic transitions that are observed in the pre-edge
XANES region of the K-edge spectra in both the samples (Figure 3.11). The peak area
intensities of the 1s  3d transitions depend on the coordination number and geometry of
the metal sites116,

117

.

By comparing the 1s  3d transition peak areas of the PHD2

samples with typical values for known coordination numbers/geometries we were able to
determine the coordination numbers of both the PHD2 samples from the XANES data as
being five-coordinate.
Comparisons of XANES data (Table 3.3, Figure 3.11) for the two PHD2 samples show
that each spectrum is distinct. Thus, the structure of the iron site is sensitive to pH. The
lowering of K-edge energy from pH 6.5 to pH 8.5 indicates an increase in electron
density at the iron site. The edge energies observed for Fe2+:αKG:PHD2 at pH 6.5 and at
pH 8.5 are 7121.2 eV and 7120.9 eV respectively. No changes in the coordination
number of the Fe(II) center are apparent at pH 6.5 or at pH 8.5. In the PHD sample at pH
6.5 the 1s  3d peak area (~ 8.7 x 10-2 eV) is indicative of a five-coordinate complex
(typical values are ~8 – 13 x 10-2 eV). The complex remains five-coordinate with a 1s 
3d peak area of ~7.9 x 10-2 eV upon increasing the pH to 8.5.

70

EXAFS Analysis
The analysis of EXAFS provides information about the number and types of ligands
bound to a metal, and metric details of the metal site structure. This information is
obtained from the best fits of the data and is summarized in Figure 3.12, Table 3.3. The
best fit for Fe2+:αKG:PHD2 at pH 6.5 EXAFS data consists of six N/O donor ligands of
which two are imidazoles from multiple-scattering analysis. Using the chelate model, C

k3χ(k)

FT magnitude

atoms are found at 2.75 Å and 2.85 Å.

k (Å-1)

r (Ǻ)

Figure 3.12 EXAFS analysis. Left: Unfiltered, k3-weighted EXAFS spectra Fe(PHD)αKG at pH 6.5 (top) and at pH 8.5 (bottom) and fits (black lines). Right: Fouriertransformed EXAFS data and fits.
The best fit for Fe2+:αKG:PHD2 at pH 8.5 EXAFS data also consists of six N/O donor
ligands of which two are imidazoles from multiple-scattering analysis (Table 3.3). But
the average bond lengths are shorter than those at pH 6.5. Using the chelate model, two
C atoms are found at 2.62 and 2.72 Å. Considering the Fe-N/O bond lengths at pH 6.5
and 8.5 it can be predicted that the N/O donor at 1.96 Å could be due to the hydroxide
formation (Fe-OH will be shorter than Fe-OH2). This is in agreement with the decrease in
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Fe K-edge energy due to the increase of pH from 6.5 to 8.5 (OH will make Fe center
more electron rich than OH2).

Solvent Isotope Effects on PHD2
In lieu of the discovery of a titratable pKa, visible differences in the spectra at pH 6.5 and
pH 8.5 and in no small part based upon the radial bond length changes in the acid-base
forms of PHD2 we turned to SIE experiments. SIE may potentially help to determine if
further mechanistic information could be obtained with emphasis on the step involving
the six coordinated water molecule release from iron, see figure 3.13.

Figure 3.13 Individual steps believed to be involved in the catalysis of PHD2. Based
upon pH and SIE studies focus is on k5 where the release of water is thought to occur
opening an open coordination site for O2 activation with the iron(II)state maintained.

PHD2 was assayed under the identical conditions as that for determining pH effects on its
catalytic activity by the collection of full Michaelis-Menten type kinetic curves (Figure
3.14).
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Figure 3.14 Kinetic fits for PHD2 at varied pD. All assays include 0.3 µM PHD2, 15
µM ferrous ammonium sulfate, 200 µM αKG, 2 mM ascorbic acid and ODDD
concentrations from 0-50 µM. Product formation was calculated using the equation
[ODDDOH] = (ODDD-OH) x [ODDD]0 for all initial rates which comprise the kinetic
curves.
The exception is the replacement of H2O for D2O in all buffers and stocks of required
materials. The solvent isotope effects on kcat, KM, and kcat/KM were measured to test the
relative rate constants for water binding and release to other steps in the chemical
mechanism. The resulting data indicated an inverse solvent isotope effect where kcatH/
kcatD is 0.91 ± 0.03 and the observed pKa is 7.89 ± 0.03 which results in a pKa shift of 0.67
± 0.04 from that at H2O.(Figure 3.15). Based on fractionation factors for similar metal73

water complexes this ΔpKa shift of 0.67±0.04 is agreement for other metalloenzymes
such as the zinc-bound water in alcohol dehydrogenase (ΔpKa 1.04), xanthine oxidase
(ΔpKa ~1), and carbonic anhydrase I and II (ΔpKa 0.37-0.54)101,

121-124

. The kinetic

parameters obtained are listed in table 3.4.

Figure 3.15 Solvent isotope effects, (D2O, triangles, H2O, squares) pKa fits for PHD2.
Data is comprised of full Michaelis-Menten curves for each data point. Fully protonated
form, 2.99 ± 0.08, pKa 7.22 ± 0.03, deprotonated 0.31 ± 0.02. Fully deuterated form 3.3
± 0.06, pKa 7.89 ± 0.03, dedeuterated form 0.34 ± 0.04. The observed solvent isotope
effect on kcat is 0.91 ± 0.03.
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pD

kcat, min-1

KM µM

kcat/KM, µM-1min-1

kcat/KM, µM-1min-1
Using averaged KM

6.40

3.04 ± 0.09

2.27 ± 0.51

1.33 ± 0.30

1.75 ± 0.58

6.60

3.14 ± 0.09

2.33 ± 0.38

1.35 ± 0.23

1.82 ± 0.60

7.05

3.16 ± 0.09

2.06 ± 0.39

1.53 ± 0.29

1.83 ± 0.60

7.13

2.71 ± 0.11

1.35 ± 0.26

2.00 ± 0.39

1.57 ± 0.52

7.25

2.96 ± 0.14

1.92 ± 0.41

1.54 ± 0.34

1.71 ± 0.57

7.58

2.57 ± 0.09

1.60 ± 0.42

1.60 ± 0.43

1.49 ± 0.49

7.78

1.68 ± 0.07

0.58 ± 0.27

2.89 ± 1.35

0.97 ± 0.32

7.95

1.91 ± 0.06

1.25 ± 0.00

1.53 ± 0.05

1.10 ± 0.37

8.13

1.28 ± 0.05

1.25 ± 0.00

1.00 ± 0.04

0.73 ± 0.25

8.40

1.29 ± 0.07

1.50 ± 0.00

0.86 ± 0.05

0.75 ± 0.25

9.05

0.52 ± 0.03

0.21 ± 0.22

2.48 ± 2.60

0.30 ± 0.10

Table 3.4 Kinetic parameters for PHD2 under different pD values. All data was obtained
by linear regression of the initial rates collected under varied ODDD concentration (1-50
µM), and then fitted to the Michaelis-Menten equation to obtain kcat and KM.
A similar event occurs with regards to the accuracy of the KM as it did in H2O buffers in
which current detection methods hinder the ability to definitively assign a viable value to
this parameter. In H2O KM values range from 0.18-3.13 µM, in D2O KM ranges from
0.21-2.33 µM. The exceptionally low range of KM is only observed in the pL range above
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eight. In short this makes it difficult to know with certainty the specificity constant
kcat/KM. A plot of KM showing the observed scattering is show in Figure 3.16.

Figure 3.16 KM under various pD’s. All assays include 0.3 µM PHD2, 15 µM ferrous
ammonium sulfate, 200 µM αKG, 2 mM ascorbic acid and ODDD concentrations from
0-50 µM. Product formation was calculated using the equation [ODDDOH] = (ODDD-OH) x
[ODDD]0. The KM was derived from fitting the data to the Michaelis-Menten equation.
Overall the KM values with the exception of a few outliers are somewhat similar and an
averaging of the KM generates a value of 1.73 ± 0.57 which is over all much lower than
that calculated for the H2O KM value of 1.67 ± 0.32 µM. If we plot kcat/KM with the
unadjusted values we are unable to obtain any gainful information. If we assume the KM
does not actually shift about which is not unreasonable considering the nature of the data
we obtain we are then able to provide a conservative idea of the impact D2O imparts upon
kcat/KM (Figure 3.17).
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A

B

Figure 3.17 kcat/KM in D2O, A) kcat/KM using KM generated from Michaelis-Menten fits.
B) kcat/KM using an averaged KM (1.73 ± 0.57) which assumes little if any fluxuation in
the value as the actual KM is below the detection limits of data collection.
As previously mentioned inverse solvent isotope effects which arise in enzyme-catalyzed
reactions have been attributed to the acid dissociation constant of a thiol, a diffusionsensitive conformational change arising from solvent viscosity effects, or the dissociation
of metal-chelated water102-105. PHD2177-426 contains seven cysteine residues all of which
are distally located to the active site pocket. Based on this fact the inverse solvent
isotope effect witnessed is excluded as originating from the acid dissociation of thiol
groups. Thus, the other two plausible reasons giving rise to the observed inverse SIE are
the dissociation of a metal-H2O bond or solvent viscosity effects. To confirm or rule out
viscosity as the underlying cause we initiated experiments in which we increased the
viscosity of the H2O buffers.
Viscosity Assays
It has been concluded in previous work that mere external viscosity changes to a reaction
mixture are enough to elicit rate changes in an enzyme-substrate mechanism104, 105. The
impact generated by viscosity in some systems has been suggested to influence the rate-
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limiting step which is in effect the rate of necessary transition states required to proceed
past the energy barrier in order to achieve product accumulation. The viscosity of the
medium also has the ability to impart an inverse solvent isotope effect125. To eliminate
the potential that the observed inverse SIE is simply the result of viscosity, assays which
introduced a visocogen were conducted.

The addition of 10% sucrose to a non-

deuterated 50 mM HEPES pH 7.0 buffer was introduced to mimic the viscosity imposed
by D2O. The relative viscosity (η/ηo) of D2O at 37°C is 1.31 mPa*s. The relative
viscosity of a 10% sucrose solution at 20°C is 1.333 at 37°C it is approximately 1.3
mPa*s and therefore approximates the relative viscosity of D2O. The results support that
the viscosity is not a factor in the catalytic differences observed between H 2O and D2O
(Figure 3.18). The control assays in standard MPH H2O buffer generate initial rate
values of 2.07 ± 0.05 min-1, and in the same buffer with 10% sucrose the rate is 2.04 ±
0.02 min-1.

Figure 3.18 The solvent viscosity impact on PHD2. Assay includes 0.3 µM PHD2, 15
µM ferrous ammonium sulfate, 200 µM αKG, 1 mM ascorbate and 10 µM ODDD.
Activity is measured as previously disclosed. A maximal velocity of 2.07 ± 0.05 min-1
was obtained for the control assay, and in the same buffer with 10% sucrose the observed
rate is 2.04 ± 0.02 min-1.
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Having now eliminated two of the three factors which may give rise to the rarely
witnessed inverse SIE, acid-dissociation of a thiol group and viscosity we conclude that
the resultant effect is due to the dissociation of the metal-aquo bond which shifts from
Fe(II)-OH2 to Fe(II)-OH

Conclusions
Herein we report an observable dependence on pH for the catalytic mechanism of PHD2
based upon a titratable pKa of 7.22 ± 0.03. The kinetic parameter of kcat is determined to
be 2.99 ± 0.08 min-1 in the fully protonated form and 0.31 ± 0.02 min-1 in the
deprotonated state.

As previously mentioned accurate assessment of kcat/KM was

unobtainable due to the detection limits of the analysis method for substrate accumulation
under 1 µM in the reaction vessel. Equivalent experiments in D2O support a pKa shift of
0.67 ± 0.04 and a kcat of 3.30 ± 0.06 min-1 in the fully protonated form and 0.34 ± 0.04
min-1 in the deprotonated form, with an observed SIE for kcatH/ kcatD of 0.91 ± 0.03. A
summary of this data is provided in (table 3.5).

H2O
D2O

kcat, min-1

pKa

2.99 ± 0.08
3.30 ± 0.06

7.22 ± 0.03
7.89 ± 0.03

Observed SIE kH/kD 0.91 ± 0.03
Table 3.5 Observed kinetic parameters of PHD2 in water and deturium, pKa and
observed SIE.
When the kinetic parameters kH/kD, VH/VD or (V/K)H/(V/K)D are larger than unity (larger
in H2O) a normal solvent isotope effect is observed. When the parameters are less than
79

unity (larger in D2O), it is called an inverse solvent isotope effect. The inverse SIE is a
rarely witnessed event and can be attributed to three underlying causes. The first cause is
due to the acid dissociation of a thiol ligand followed second and thirdly by, a diffusionsensitive conformational change arising from solvent viscosity effects, or the dissociation
of a metal-chelated water102-105 While PHD2 contains seven cysteine residues, they are
all distally located to the active site pocket and therefore acid dissociation of a thiol group
is ruled out as the cause of the inverse SIE. Viscosity experiments exclude the result as
arising from solvent viscosity effects. Therefore, this leaves us with only one option, the
dissociation of a metal-chelated water molecule. In support of this method we report the
kinetic parameters listed in table 3.5 followed up by X-ray absorption spectroscopy. The
resulting XANES and EXAFS data analysis support shortened radial bond lengths in the
pH 8.5 sample relative to the pH 6.5 sample indicative of greater electron density at the
metal site. For comparison, SyrB2, a non-heme, αKG-dependent halogenase is utilized.
The underlying chemistry of this related enzyme employs a similar consensus mechanism
as PHD2 except the end result is a halogenation reaction and not a hydroxylation. The
measured bond length of the iron-water bond in SyrB2 is 2.10 Å with a bond dissociation
energy of 6.0 Kcal/mol, and the bond length for the hydroxyl form is 1.88 Å with a
dissociation energy of 52 Kcal/mol110, 111. It is not unreasonable based on the similarity
of the iron-water bond lengths in both enzymes that the shift to iron-OH form in PHD2
would result in a similar shortened bond length observed at 1.96 Å and greater
dissociation energy, thereby making less readily available the empty coordination site
necessary for oxygen activation to occur. The variation in OH-iron bond lengths of
SyrB2 and PHD2 at 1.88 Å and 1.96 Å respectively may in part result from a difference
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at their facial triad in which the Glu/Asp residue coordinates to SyrB2 in a bidentate
manner versus a mono-dentate fashion in PHD2. To further support our model we
present data which indicates that PHD2 activity begins to sharply drop off in a pH range
deemed biologically relevant (pH 7.2) while the stability of the enzyme is maintained.
This drop in activity without loss in stability is observable in the range of the calculated
pKa for PHD2 at 7.22 ± 0.03 in H2O as would be expected. This data coupled with the
fact that the only observable intermediate in the catalytic cycle that has been observed for
PHD2 is a Fe(II) form. At this point we need to revert back to our model for each step in
the cycle (Figure 3.19)126.

Figure 3.19 The catalytic cycle of PHD2
There are two points in the mechanism in which the accumulation of an Fe(II)
intermediate is likely. The first is at k5 which is where the water molecule departs,
opening a site for O2 activation. The second is k10 and or k11 where release of product
and succinate is likely to occur. It seems more plausible that the release of succinate and
product are more favorable as the rate determining step since the water release is going to
have a more rapid dynamic equilibrium and therefore contribute less hindrance to the
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forward commitment of the reaction. Despite this assumption the evidence supports that
the dissociation of the metal-OH2 ligand is at least in part a contributing factor towards
halting the forward commitment of the overall catalytic reaction of PHD2.
When looking at comparable enzymes such as TauD no SIE is observed suggesting that
the water-off form of the enzyme is favored as compared to the water-on form of PHD2
that generates a small inverse SIE and that product release in TauD is the slow step of the
reaction113. It is highly probably that product release is the rate-limiting step for PHD2 as
well with a small contribution from the metal-aquo ligand. In Xanthine hydroxylase, also
Fe(II), αKG dependent, SIE experiments support little effect on KM, as is the case with
PHD2 and a 40% reduction on Vmax when H2O was substituted with D2O suggesting an
exchangeable proton in the rate-determining step of the overall reaction127. However the
decrease in Vmax is more likely the result of general acid/base side chain than the
metallocenter which can give rise to an inverse SIE as appears to be the case with PHD2
where the reaction is faster in D2O. PHD2 unlike many of its related counterparts reacts
very slowly with O2 which may help explain the observed SIE. In TauD the introduction
of substrate increased the coupled turnover 1000-fold from that of the uncoupled reaction
in the absence of substrate, in PHD2 only a 30-fold increase is observed and the
uncoupled activation of O2 is on the order of 0.013 s-1 126. This is likely indicative of
PHD2’s role as an oxygen sensor and the virtually non-existent uncoupled turnover
(Appendix figure A1) provide further support for the water-on form of PHD2 which may
limit the activation of oxygen by blocking the coordination site on the iron. Overall the
dilatory reaction of PHD2 distinguishes it from any closely or distantly related enzymes.
The observed inverse SIE witnessed for PHD2 has not been reported for any closely
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related enzymes like other prolyl/proline hydroxylases nor any Fe(II), αKG dependent
hydroxylases that is linked to the metallocenter further distinguishing it in its class.
There are reports of inverse SIE’s for metalloenzymes but the result has been linked to
viscosity effects alone104, 125. The viscosity experiments conducted in this body of work
have eliminated it as the underlying cause of the inverse SIE.
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APPENDIX: Supplementary Data
Abbreviations
4NCat, 4-nitrocatechol
KG, alpha-ketoglutarate;
BuCat, 4-tert-butylcatechol
CNP, 3-cyano-6-methyl-2(H) pyridinone
CS2, clavaminate synthase-2
CTAD, C-terminal transactivation domain of HIF-1 ;
DHP, 2,3-dihydroxypyridine
ESI-MS, electrospray ionization mass spectrometry;
FIH-1, the factor inhibiting HIF
HIF, Hypoxia Inducible Factor
Hop-COOH, 5-hydroxy-4-oxo-4H-pyran-2-carboxylic acid
Hop-Me, 3-hydroxy-2-methyl-4-pyrone
Hop-OH, 5-hydroxy-2-hydroxymethyl-4-pyrone
HOPO, 3-hydroxy-1,2-dimethyl-4(1H)-pyridinone
HPCD, homoprotocatechuate 2,3-dioxygenase
HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid;
MeCat, 4-methylcatechol
MLCT, metal-to-ligand charge transfer
NOP, 2-hydroxypyridine 1-oxide
ODDD, oxygen dependent degradation domain
p300, transcriptional coactivator
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PHD2, Prolyl Hydroxylase Domain 2
SIE, solvent isotope effect
TauD, taurine dioxygenase
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pGEX-4T-1-PHD2 DNA Sequence and Plasmid Insertion Details
pGEX-4T-1 sequence
Full length: 4969 bp; PHD2 insert:
1
61
121
181
241
301
361
421
481
541
601
661
721
781
841
901
3694
3754
3814
3874
3934
4094
4154
4214
4274
4334
4394
4454
4514
961
1021
1081
1141
1201
1261
1321
1381

744 bp

ACGTTATCGA CTGCACGGTG CACCAATGCT
GTATGGCTGT GCAGGTCGTA AATCACTGCA
TCTGGATAAT GTTTTTTGCG CCGACATCAT
TGTTGACAAT TAATCATCGG CTCGTATAAT
CACAGGAAAC AGTATTCATG TCCCCTATAC
AACCCACTCG ACTTCTTTTG GAATATCTTG
GCGATGAAGG TGATAAATGG CGAAACAAAA
TTCCTTATTA TATTGATGGT GATGTTAAAT
TAGCTGACAA GCACAACATG TTGGGTGGTT
TTGAAGGAGC GGTTTTGGAT ATTAGATACG
TTGAAACTCT CAAAGTTGAT TTTCTTAGCA
ATCGTTTATG TCATAAAACA TATTTAAATG
TGTATGACGC TCTTGATGTT GTTTTATACA
AATTAGTTTG TTTTAAAAAA CGTATTGAAG
CCAGCAAGTA TATAGCATGG CCTTTGCAGG
ATCCTCCAAA ATCGGATCTG GTTCCGCGTG
CGGCCCAACG GGCAGACCGG CAGAAGCCCC
TCGTGCCGTG CATGAACAAG CATCTGTGTG
CAGCAGATCG GCGACGAGGT GCGCGCCCTG
CTGGTCAGCC AGAAGAGTGA CTCGTCCAAG
GAGGGCAAGG AGCCCGGCTG CGAAACCATT
ATACGCCACT GTAACGGGAA GCTGGGCAGC
GTTGCTTGTT ATCCGGGCAA TGGAACGGGT
GATGGAAGAT GTGTGACATG TATATATTAT
GGAGGTATAC TTCGAATTTT TCCAGAAGGC
TTTGATAGAC TGCTGTTTTT CTGGTCTGAC
TATGCTACAA GGTACGCAAT AACTGTTTGG
AAAGTAAAAT ATCTAACAGG TGAAAAAGGT
TCGGTCGGTA AAGACGTCTT CTAG
GA ATTCCCGGGT CGACTCGAGC
GGCCGCATCG TGACTGACTG ACGATCTGCC
TCTGACACAT GCAGCTCCCG GAGACGGTCA
GACAAGCCCG TCAGGGCGCG TCAGCGGGTG
AGTCACGTAG CGATAGCGGA GTGTATAATT
TATTTTTATA GGTTAATGTC ATGATAATAA
GGGGAAATGT GCGCGGAACC CCTATTTGTT
CGCTCATGAG ACAATAACCC TGATAAATGC
GTATTCAACA TTTCCGTGTC GCCCTTATTC

TCTGGCGTCA
TAATTCGTGT
AACGGTTCTG
GTGTGGAATT
TAGGTTATTG
AAGAAAAATA
AGTTTGAATT
TAACACAGTC
GTCCAAAAGA
GTGTTTCGAG
AGCTACCTGA
GTGATCATGT
TGGACCCAAT
CTATCCCACA
GCTGGCAAGC
GATCCCCG
TGCCGGCGCT
GTGGACGACT
CACGACACCG
GACATCCGAG
GGGCTGCTCA
TACAAAATCA
TATGTACGTC
CTTAATAAAG
AAAGCCCAGT
CGTCGCAACC
TATTTTGATG
GTGAGGGTTG

GGCAGCCATC
CGCTCAAGGC
GCAAATATTC
GTGAGCGGAT
GAAAATTAAG
TGAAGAGCAT
GGGTTTGGAG
TATGGCCATC
GCGTGCAGAG
AATTGCATAT
AATGCTGAAA
AACCCATCCT
GTGCCTGGAT
AATTGATAAG
CACGTTTGGT

GGAAGCTGTG
GCACTCCCGT
TGAAATGAGC
AACAATTTCA
GGCCTTGTGC
TTGTATGAGC
TTTCCCAATC
ATACGTTATA
ATTTCAATGC
AGTAAAGACT
ATGTTCGAAG
GACTTCATGT
GCGTTCCCAA
TACTTGAAAT
GGTGGCGACC

GAAGCTGGCG
TCCTCGGCAA
GGAAGTTCAC
GCGATAAGAT
TGAGCAGCAT
ATGGCCGGAC
ATGTTGATAA
ACTGGGATGC
TTGCTGACAT
CTCATGAAGT
CAGATGAGAG
AACTCAATAA

CTCGAGTACA
GGAGACCGGA
GGACGGGCAG
CACCTGGATC
GGACGACCTG
GAAAGCCATG
TCCAAATGGA
CAAGGTAAGT
TGAACCCAAA
ACAACCAGCA
AGCACGAGCT
ACCTTCAGAT

TCGCGCGTTT
CAGCTTGTCT
TTGGCGGGTG
CTTGAAGACG
TGGTTTCTTA
TATTTTTCTA
TTCAATAATA
CCTTTTTTGC

CGGTGATGAC
GTAAGCGGAT
TCGGGGCGCA
AAAGGGCCTC
GACGTCAGGT
AATACATTCA
TTGAAAAAGG
GGCATTTTGC

GGTGAAAACC
GCCGGGAGCA
GCCATGACCC
GTGATACGCC
GGCACTTTTC
AATATGTATC
AAGAGTATGA
CTTCCTGTTT

The green codon signifies the start codon for the GST-pGEX sequence, the primers highlighted in
yellow indicate the forward and reverse annealing sites for the pGEX sequencing primers. The
red sequences are BamH1 and EcoR1 restriction enzyme cut sites respectively.
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Sequence Alignment of Full Length PHD2 versus PHD2 Catalytic Domain used for
all Experimental Procedures
100.0% identity in 250 residues
PHD2 Cut
Full PHD2

1 GGLRPNGQTKPLPALKLALEYIVPCMNKHGICVVDDFLGKETGQQIGDEVRALHDTGKFT
177 GGLRPNGQTKPLPALKLALEYIVPCMNKHGICVVDDFLGKETGQQIGDEVRALHDTGKFT

PHD2 Cut
Full PHD2

61 DGQLVSQKSDSSKDIRGDKITWIEGKEPGCETIGLLMSSMDDLIRHCNGKLGSYKINGRT
237 DGQLVSQKSDSSKDIRGDKITWIEGKEPGCETIGLLMSSMDDLIRHCNGKLGSYKINGRT

PHD2 Cut
Full PHD2

121 KAMVACYPGNGTGYVRHVDNPNGDGRCVTCIYYLNKDWDAKVSGGILRIFPEGKAQFADI
297 KAMVACYPGNGTGYVRHVDNPNGDGRCVTCIYYLNKDWDAKVSGGILRIFPEGKAQFADI

PHD2 Cut
Full PHD2

181 EPKFDRLLFFWSDRRNPHEVQPAYATRYAITVWYFDADERARAKVKYLTGEKGVRVELNK
357 EPKFDRLLFFWSDRRNPHEVQPAYATRYAITVWYFDADERARAKVKYLTGEKGVRVELNK

PHD2 Cut
Full PHD2

241 PSDSVGKDVF
417 PSDSVGKDVF

The full length PHD2 sequence is as follows:
MANDSGGPGG
SEGALGHGVG
AAAASPCRAA
PNGQTKPLPA
VSQKSDSSKD
ACYPGNGTGY
DRLLFFWSDR
VGKDVF

PSPSERDRGY
PHQHSQPAPP
AGGGSAVAA
LKLALEYIVP
IRGDKITWIE
VRHVDNPNGD
RNPHEVQPAY

CELCGKMENL
AAVPPPRAGA
EAEPGKEEPP
CMNKHGICVV
GKEPGCETIG
GRCVTCIYYL
ATRYAITVWY

LRCSRCRSSF
REPRKAAARR
ARSSLFQEKA
DDFLGKETGG
LLMSSMDDLI
NKDWDAKVSG
FDADERARAK
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YCCKENHGRGD
DNASGDAAKG
NLYPPSNTPG
GIGDEVRALH
RHCNGKLGSY
GILRIFPEGK
VKYLTGEKGV

WKKHKLVCGG
KVKAKPPADP
DALSPGGGLR
DTGKFTDGGL
KINGRTKAMV
AQFADIEPKF
RVLNKPSDS

PHD2 Executes a Tighty Coupled Reaction in the Presence of Prime Substrate
As PHD2 is deemed one of the primary oxygen sensors it would seem likely that it the
overall reaction mechanism is tightly coupled. By tightly coupled we imply that turnover
results in equivalent amounts of the products succinate and hydroxyl proline. If we
witness production of succinate greater than that for hydroxyl proline this suggests that
the enzyme activates oxygen at the iron center generating a highly reactive intermediate
that is capable of hydroxylating any viable target within a defined radius. If this were the
case, it would make PHD2 a poor oxygen regulator as the result of this uncoupled
reaction would lead to cellular damage from oxidative products.
To test the coupling of PHD2 to hydroxyl proline assays were performed in which the
succinate production was measured and compared to the accumulation of hydroxylated
ODDD.

A succinate detection kit was employed (Succinic Acid, UV-method,

Boehringer Mannheim / R-Biopharm) following the manufactures protocol. Detection of
ODDD-OH follows the previous protocols mentioned in this thesis.
The resulting coupling ratio was determined to be 0.93 ± 0.1, indicating that reaction is
tightly coupled as would be thought for an enzyme that functions as an oxygen sensor.
This assay also provided a secondary support method validating our mass spectrometry
method of determining initial rate values (Figure A1).
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Figure A1 Succinate production as compared to ODDD-OH production to determine
coupling ratio. PHD2 1.0 µM, ferrous ammonium sulfate 20 µM, αKG 500 µM, 2 mM
ascorbate, 80 µM ODDD.
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